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 Since Rosenzweig’s “Dodo Bird Verdict” in 1936, the “common” versus 
“specific” factors debate has continued to polarize the field of psychotherapy. Treatment 
expectancy is an important but often overlooked common factor. The current study 
investigated the role of treatment expectancy in the Treatment of Adolescents with 
Depression Study (TADS). Four-hundred three adolescents (Mage=14.62, SD=1.56) filled 
out the Treatment Expectancy for Adolescents (TEA) measure prior to treatment 
randomization to one of four treatments: fluoxetine (FLX), cognitive behavior therapy 
(CBT), their combination (COMB), and placebo (PBO). Adolescents randomized to CBT 
or COMB also filled out the CBT Rationale Acceptance and Expectation for 
Improvement (C-RAEI) form during their second session of CBT. 
 Before finding out their treatment assignments, adolescents endorsed higher 
treatment expectancies for COMB than CBT and medication only. Family income levels 
below $75,000 and higher levels of depression severity, hopelessness, and suicidality 
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were associated with lower expectations for improvement with CBT. The presence of a 
comorbid anxiety disorder diagnosis was associated with lower expectations for 
medication without CBT. Separate random coefficients and logistic regression models 
identified treatment expectancy as a predictor of outcome for three primary outcome 
measures in TADS, irrespective of treatment assignment. Severity of depression 
moderated this relationship; mild to moderately depressed adolescents appeared to be 
more sensitive to the effects of treatment expectancy than marked to severely depressed 
adolescents. The opposite results were found for the self-rated outcome measure in 
TADS based on the C-RAIE. For marked to severely depressed adolescents assigned to 
CBT or COMB, acceptance of treatment rationale and expectancy for improvement were 
associated with treatment response. 
 These results suggest that treatment expectancy is an important common factor of 
treatment for mild to moderately depressed adolescents prior to treatment initiation, 
although it may be especially important for initially skeptical, marked to severely 
depressed adolescents to “buy in” to treatment after treatment initiation. Treatment 
effects were still found after controlling for the effects of treatment expectancy on 
outcome. It seems that both the “common” factor of treatment expectancy and the 
“specific” factor of treatment assignment contributed to outcome in TADS.   
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CHAPTER I 
INTRODUCTION 
 
For more than 50 years, researchers have speculated on the role of expectancy in 
psychotherapeutic outcome (Frank, 1958, 1968; Greenberg, Constantino, & Bruce, 2006). 
Preceding Smith and Glass’ (1977) controversial meta-analysis concluding that 
psychotherapies produce similar outcomes due to the “common factors” of therapy (i.e. 
underlying factors, such as therapeutic alliance, that cut across different treatment 
modalities) as opposed to the “specific factors” of therapy (i.e. case formulations and 
techniques specific to a given therapy), Frank (1973) identified “outcome expectancy,” 
defined as expectancy for improvement, as a common factor inherent in many forms of 
healing, including psychotherapy, shamanistic healing, and improvement with placebo. 
Related constructs in psychology include the “self-fulfilling prophecy” (Merton, 1948) 
and “response expectancy” (Kirsh, 1985), both of which describe how expectations 
precede and influence future events through changes in a person’s behavior.  
Despite early interest in expectancy and its influence on treatment outcome, 
research in this area has been sporadic and inconclusive. Some studies have found a 
positive association between expectancy and improved outcome (Sotsky et al., 1991; 
Chambless & Tran, 1997; Price, Anderson, & Henrich, 2008), while other studies have 
not demonstrated such a relationship (Borkovec, Newman, Pincus, & Lytle, 2002; 
Chambless, Tran, & Glass, 1997). Reasons for these discrepant findings are varied and 
include the lack of standard assessments of expectancy, as well as differences in 
definitions and conceptualizations of expectancy. For example, researchers often do not 
  
2 
 
distinguish between overall expectancy for improvement with or without treatment (e.g. 
“I expect things will get better over time.”) and expectancy particular to a given treatment 
(e.g. “Tylenol will cure my headache.”). This distinction is important because overall 
expectancy and treatment expectancy may correlate with different variables (e.g. 
hopefulness and belief in a “just world” in the case of overall expectancy and acceptance 
of treatment rationale in the case of treatment expectancy), and arguably are not same 
construct. Other reasons for the discrepant findings in the expectancy literature include 
differences between sample participants and treatments, blinding procedures, statistical 
analyses, and sequencing of assessments.  
Given its potential impact on treatment outcome, surprisingly little research has 
been devoted to clarifying the role of expectancy in treatment. Indeed, Weinberger and 
Eig (1999) have labeled expectancy “the ignored common factor in psychotherapy” (pg. 
357). This is in spite of the fact that the majority of psychotherapies, as well as 
pharmacotherapies, include providing a rationale for treatment to clients (in the case of 
psychology), patients (in the case of psychiatry), and participants (in the case of research) 
as an important first step of treatment. For example, researchers in the area of stress 
management, Shaw and Blanchard (1983), concluded,  
Giving participants a high initial expectation of therapeutic benefit from 
stress management training has significant benefit in terms of change and 
reduced physiological reactivity…the procedures, per se, are not 
especially powerful without the appropriate set (pg. 564). 
 
However, the importance of such an “appropriate set” has not been convincingly 
demonstrated; it is unclear to what extent treatment expectancy influences treatment 
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outcome. Also, few studies have investigated possible mediators and moderators of the 
relationship between treatment expectancy and outcome. 
The main purpose of my dissertation is to better understand the role of treatment 
expectancy in determining treatment outcome through a closer examination of the 
Treatment for Adolescents with Depression Study (TADS). Previous expectancy research 
has focused primarily on adults in studies with one or two treatment conditions. TADS 
provides a unique opportunity to investigate the role of expectancy in adolescents with 
depression randomly assigned to Cognitive Behavioral Therapy (CBT), fluoxetine (FLX), 
the combination of the two treatments (COMB), and placebo (PBO). Despite an 
impressive number of studies investigating the efficacy and effectiveness of various 
treatments for depression over the past several decades, it is still unclear who will 
respond to a particular treatment and through what mechanism(s). This is particularly true 
for the treatment of adolescents with depression. By understanding the role of treatment 
expectancy in TADS, it may be possible to improve treatment matching strategies and 
response rates for this growing population. More broadly, this area of research has 
implications for blinded, randomized clinical research trials and the common versus 
specific factors debate in psychotherapy research.  
 
Response Expectancy 
 
Treatment expectancy falls under the broader category of “response 
expectancies.” Kirsch (1997) defined response expectancy as “the anticipation of 
automatic, subjective, and behavioral responses to particular situational cues (pg. 69).” 
He discusses the power of response expectancy with the example of Southworth and 
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Kirsch’s 1988 study on the effects of in vivo exposure on agoraphobia. Participants were 
asked to walk away from their home ten times during a two-week period until they 
became anxious and then to return home. Half of the participants were told that the 
purpose of this exercise was to reduce their anxiety over time, while the other half were 
told that this was part of the assessment process preceding treatment. The first group 
reported greater and more rapid reductions in anxiety levels compared with the latter 
group who were led to believe that their anxiety levels would not go down during this 
time. Kirsch asserts that the therapeutic effects of in vivo exposure can be “suppressed” 
by manipulating response expectancies or “disguising” a treatment’s therapeutic intent 
(pg. 71). Alternatively, the study also suggests that response expectancy may account for 
a significant amount of the effects of exposure therapy. 
 Numerous other examples of the powerful effects of response expectancy exist in 
the literature, including studies indicating physiological changes and improved motor 
task performance (Fillmore & Vogel-Sprott, 1992; Kirsch & Weixel, 1988) and the 
induction of symptoms of mass psychogenic illness (Lorber, Mazzoni, & Kirsch, 2007). 
In Lorber, Mazzoni, and Kirsch’s 2007 study, participants who believed they had inhaled 
environmental toxins experienced symptoms specific to the type of toxin. The 
investigators concluded that response expectancy is specific to one’s expectations. Thus, 
if an individual believes that an antidepressant will improve only his/her symptoms of 
depression (e.g. feeling “blue”), changes in the person’s anxiety levels would not be 
explained by response expectancy alone. 
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The Placebo Effect 
According to Kirsch, among the various examples of response expectancy effects, 
the placebo effect is its “prototype” (pg. 70; Kirsch, 1997). The placebo, often consisting 
of little more than sugar, is commonly referred to as an “inactive” substance or treatment. 
However, research subjects who are assigned to the placebo condition in these studies 
often actively respond to placebo pills, presumably through response expectancy effects. 
While there are a growing number of researchers involved in investigating the placebo 
effect in pharmacological clinical research trials, most researchers continue to regard the 
placebo effect as a nuisance to be minimized. The placebo effect is seen as “noise,” 
masking the effects of the comparison treatment(s) under investigation.  
While the placebo effect has a relatively long history in treatment outcome 
research, Hrobjartsson and Gotzsche (2004) found no evidence for a placebo effect in 
their meta-analysis, which included studies investigating treatments for 46 clinical 
conditions, including nausea, smoking, and depression. Wampold and colleagues (2005) 
criticized this particular meta-analysis for its use of such diverse clinical conditions and 
separated the same studies based on adequacy of study design and the degree to which 
disorders were amenable to psychological factors (as rated by independent evaluators). 
The results of this re-analysis indicated the presence of a placebo response in studies of 
conditions judged to be amenable, or susceptible to psychological factors, such as 
depression, insomnia, and chronic pain, as opposed to bacterial infection and anemia. For 
conditions judged to be amenable to the placebo effect, participants assigned to placebo 
were more likely to improve than participants assigned to wait-list or no-treatment. 
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Indeed, participants receiving placebo demonstrated rates of improvement approaching 
those of participants receiving “active” medications, such as antidepressants. 
Interestingly, research suggests that depression is particularly susceptible to the 
placebo effect. In an analysis of the results of meta-analyses across the major mental 
disorders in the mid-1980’s conducted by the Quality Assurance Project (1982-1985), 
Andrews (2001) reported that depression had the highest rates of placebo response, 
followed by generalized anxiety disorder, agoraphobia, obsessive-compulsive disorder, 
and schizophrenia, which was not shown to have a placebo effect. Andrews speculated 
that depression is the most sensitive to the encouraging effect of being in treatment, 
highlighting depression’s high spontaneous remission rates (Kendler et al., 1997; 
McLeod, et al. 1992).  
Notably, effect sizes for the drug treatments included in Andrews’ analysis ranged 
from .44 to more than ten times this effect size at 4.77, while the effect sizes for the 
placebo treatments ranged from .10 to more than twenty times this effect size at 2.28. For 
the psychotherapy conditions, the effect sizes ranged from .67 to 2.87, while the effects 
for the wait-list/no-treatment control conditions ranged from -1.45 to -.28. The wide 
range of effect sizes across these various treatments suggests that there are a number of 
factors that contribute to outcome besides the specific effects of individual treatments. 
One factor that may contribute to the variability of drug-placebo differences between 
studies is differences in integrity of the blind. Effective blinding procedures minimize 
expectancy effects, while ineffective blinding procedures do not. 
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Double-Blind, Placebo-Controlled Clinical Research Trials 
Double-blind, placebo-controlled clinical research trials are the “gold standard” in 
treatment outcome research within the field of psychiatry (Day & Altman, 2000). 
Medications are deemed effective if they are able to outperform placebo in studies where 
treatment expectancy effects are minimized through the use of “blinded” conditions. A 
study is considered “double-blind” when both study participants and independent 
evaluators are unaware of participants’ assigned treatment conditions. Based on the gold 
standard status of double-blind, placebo-controlled clinical research trials and the 
Consolidated Standards of Reporting Trials’ (CONSORT) recommendation for 
researchers to routinely report on the integrity of study blindness (Moher, Schulz, & 
Altman, 2001) it seems that an underlying assumption in psychiatry (and medicine in 
general) is that treatment expectancy is, indeed, quite powerful and necessary to control 
for through the use of placebo. Yet the integrity of blind of clinical research trials is 
seldom assessed. 
Between 1998 and 2001, only eight of 94 double-blind trials with adult 
populations published in four of the top-tier psychiatry journals assessed the success of 
blinding procedures with half of these studies indicating “imperfect” blind (Fergusson, 
Glass, Waring, & Shapiro, 2004). Previous studies have found that between 67-88% of 
independent evaluators and research participants are able to correctly identify 
participants’ treatment conditions (Brownell & Stunkard, 1982; Margraf et al., 1991; 
Rabkin et al., 1986; Vitiello, Davis, Greenhill, & Pine, 2006). In an earlier review of 
psychotropic drug trials, Fisher and Greenberg (1993) found that 23 of 26 double-blind 
adult studies reported patients and/or physicians were able to differentiate active from 
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placebo conditions at rates significantly greater than chance, raising questions regarding 
the validity of published study results (Fisher & Greenberg, 1993). 
However, since most assessments of blinding occur at the end of research trials, it 
is often difficult to determine if a breakdown of blind precedes or follows symptom 
improvement. In the latter case, independent evaluators and research participants may 
base their treatment attributions on symptom improvement, and the study’s validity is not 
threatened. As stated by Senn (2004), “The whole point of a successful double-blind trial 
is that there should be un-blinding through efficacy… If the treatments are not 
distinguishable at all, then the treatments have not been proved different (pg. 1135).” 
Essentially, a study remains valid if attribution to active treatment occurs across 
conditions based on symptom improvement alone (Vitiello, Davis, Greenhill, & Pine, 
2006). In contrast, rater bias (also referred to as “observer” or “ascertainment” bias) 
occurs when rater knowledge of treatment assignment directly affects outcome ratings 
and may inflate the differences between treatment and control groups (Marcus et al., 
2006). If subjects are aware of their assigned conditions, the medication effect is likely to 
be overestimated, while the placebo effect likely to be underestimated (Sapirstein, 1995).  
Despite the likelihood that treatment expectancy effects influence treatment 
outcome in combination with imperfect blinding procedures, thus inflating drug-placebo 
differences, high rates of placebo response continue to challenge the efficacy of “active” 
medications. The high rates of placebo response in clinical research trials of 
antidepressants, especially, have been used to cast doubt on the actual efficacy of these 
medications (Kirsch & Sapirstein, 1998; Kirsch et al., 2002). In a meta-analysis of 
double-blind pharmacotherapy studies for depression, Sapirstein (1995) estimated that 
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25% of the response to antidepressants is due to the passage of time, 50% to expectancy, 
and only 25% to the “active” ingredients of medication. Interestingly, Sapirstein found 
that the placebo response was proportional to the drug response (r=.87), such that the 
greater the drug effect, the greater the placebo effect.  
Similarly, in a controversial meta-analysis, Kirsch and colleagues (2002) 
investigated the results of 47 randomized placebo controlled short-term efficacy trials 
submitted to the FDA for the six most widely prescribed antidepressant drugs approved 
within the study period (1987-1999). The authors concluded that the placebo response 
accounted for 80% of the response to these antidepressants, while the active ingredients 
of medication accounted for approximately a two point difference on the 17 and 21-item 
Hamilton Depression Scales (HAM-D-17 & HAM-D-21; Hamilton, 1960) between active 
medications and placebo, which is clinically insignificant. Based on their results, the 
investigators concluded that there is little meaningful difference between antidepressants 
and placebos in terms of short-term efficacy.  
Previous research, however, suggests that the placebo response is less likely to 
occur in more severe forms of psychopathology (Shapiro & Shapiro, 1997). Indeed, the 
ability to treat severe depression is the most noted difference between antidepressants and 
placebos (Khan et al., 2002; Wilcox et al., 1992; Fairchild et al., 1986). Moreover, as 
Kirsch and colleagues (2002) note, pharmacological effects of antidepressants are 
negligible only if drug and placebo effects are additive. It is uncertain whether or not this 
is the case since two treatments that lead to the same outcome may have different 
mechanisms for improvement. Individuals who respond well to placebo may not respond 
as well to medication and vice versa.  
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In a 2002 study using functional brain imaging of depressed male inpatients 
randomized to six weeks of placebo or fluoxetine treatment, Mayberg and colleagues 
found that treatment response for both the medication and placebo conditions was 
associated with significant regional metabolic changes in glucose metabolism in the 
neocortical and limbic-paralimbic regions of the brain. Although placebo and medication 
responders seemed to respond equally well to treatment (as measured by the HAM-D-
17), fluoxetine treatment responders generally showed greater magnitudes of change 
covering greater volumes of area in these regions. Fluoxetine response was associated 
with unique increases in brainstem metabolism and metabolic decreases in the stiratum, 
hippocampus, and anterior insula. The results of this study suggest different, although 
heavily overlapping changes in the brains of individuals who respond to placebo versus 
medication.  
In summary, placebo response rates in double-blind, placebo-controlled clinical 
research trials tend to be high, despite the fact that most participants and independent 
evaluators are able to correctly guess participants’ assigned treatments at rates exceeding 
chance level. The integrity of the blind in treatment outcome studies of pharmacotherapy 
is under-examined with the likelihood of inflated drug-placebo differences due to rater 
bias and/or treatment expectancy effects. Although the high rates of placebo response 
have cast doubt on the actual efficacy of antidepressants, it is more accurate to state that 
both placebo and antidepressant treatment are effective treatments for depression. A 
preliminary brain imaging study suggests that antidepressants and placebo response 
involves overlapping, though non-identical response pathways. Therefore, it is likely that 
there are “common” factors, such as treatment expectancy, in both antidepressants and 
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placebo that contribute to treatment response, and specific, non-overlapping factors, as 
well.  
Expectancy as a “Common Factor” in Psychotherapy Research 
 
Meanwhile, it is extremely difficult to construct a “placebo therapy” that is 
identical to the therapy under investigation minus the therapy’s “active” ingredients. As 
Klein (1997) points out, a dismantling process where specific elements of a particular 
psychotherapy will also affect other factors, such as the therapeutic nature of the 
relationship (instructional vs. collaborative, etc.), and the resulting therapy control 
condition will not be identical to the comparison treatment in all but the “active” aspects 
of the treatment. For this reason, supportive counseling or treatment as usual are used as 
comparison treatments in psychotherapy research. Supportive counseling includes 
“common” ingredients/factors (e.g. warmth, authenticity, active listening on the part of 
the therapist, and the verbal account ad organization of experience on the part of the 
client, etc.) that cut across various psychotherapies (e.g. Psychodynamic Therapy, 
Cognitive Behavioral Therapy, Person-Centered Therapy, Dialectical Behavioral 
Therapy, Acceptance and Commitment Therapy, Humanistic Therapy, Interpersonal 
Therapy, Narrative Therapy, Relational Cultural Therapy, Gestalt Therapy, Problem 
Solving Therapy, Prolonged Exposure Therapy, etc.). 
Rosenzweig (1936) was the first to identify common components or factors that 
cut across different psychotherapeutic treatment models. These so-called “common 
factors” of therapy include the factors listed above, as well as client motivation and 
expectancy, a working therapeutic relationship, client’s increased mastery and self-
esteem from therapy and the process of finding new ways to conceptualize one’s 
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problems (Parloff, 1986). According to Rosenzweig, these common factors are 
responsible for the efficacy of psychotherapy; thus, specific treatment differences have 
minimal effect on outcome. To emphasize this point, he quoted the Dodo bird from Alice 
in Wonderland, who stated, “Everybody has won, and all must have prizes” (p. 412, 
Carroll 1865).  
Since Rosenzweig’s “Dodo Bird Verdict,” a number of researchers have 
investigated the role of common factors in psychotherapy. Luborsky, Singer, and 
Luborsky (1975) reviewed the psychotherapy outcome literature and provided support for 
the Dodo Bird Verdict. Shortly thereafter, Smith and Glass (1977) were the first 
investigators to conduct a meta-analysis comparing behavioral psychotherapies to non-
behavioral psychotherapies. The investigators did not find a significant difference 
between the two types of treatment in terms of effect sizes. In a subsequent meta-
analysis, Wampold (2001) estimated that specific effects account for 8% of the variance 
in psychotherapy outcome, while common factors account for 70% of the variance, 
whereas unexplained effects account for the remainder of psychotherapy outcome 
variance (22%). These results were met with much criticism, including the averaging of 
effect sizes across outcome measures (which may blur differences in effect sizes on target 
measures), the preponderance of cognitive behavioral therapies included in the meta-
analysis, and the inclusion of a large number of studies focusing on convenience samples 
(e.g. college students) with mild symptoms (e.g. test anxiety; Crits-Christoph, 1997).  
The “common” versus “specific” factors of therapy debate continues to polarize 
psychologists in the field of treatment-outcome research. However, most would agree 
that common factors play a significant role in determining treatment outcome. Among a 
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large number of so-called “common factors,” clients’ expectancy for improvement seems 
especially important. Lambert (1992), for example, identified a four-factor model of 
change based upon his review of empirically based treatment outcome studies: 1) extra-
therapeutic change factors, 2) common factors, 3) technique factors, and 4) expectancy 
factors. Based on his review, he estimated that 40% of client improvement is based on 
client variables and extratherapy factors (e.g. the client’s environment and strengths), 
15% to specific technique factors (e.g. the “empty chair” technique in Gestalt Therapy), 
30% to relationship factors (e.g. therapist warmth), and the remaining 15% to expectancy 
effects. According to his analysis, expectancy is as important as specific treatment 
techniques and models, which is responsible for a relatively small though significant 
percentage of client improvement.  
Investigating Lambert’s four-factor model (dubbed “the Big Four”), Thomas 
(2006) asked both therapists and their clients at a university clinic to assign percentages 
to each of these four factors based on their perceived contribution to change during 
therapy.  Therapists assigned percentages in the following order on average: the 
therapeutic relationship (35%), client’s hope/expectancy (27%), client’s extra-therapeutic 
factors (22%), and specific models/techniques (16%). The mean percentages for client 
ratings were hope/expectancy (30%), the therapeutic relationship (29%), specific 
models/techniques (28%), and extra-therapeutic factors (13%). Both the therapists and 
the clients in this study attributed approximately 1/3 of change in therapy to expectancy 
effects, which is larger than Lambert had estimated. Taken together, it seems that 
researchers, therapists, and clients believe that expectancy plays a significant role in 
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treatment outcome, although disagreement exists as to what extent. This disagreement is 
reflected in treatment expectancy research within the field of psychotherapy. 
 
Expectancy in Psychotherapy Research Trials 
 
In a review of 24 studies that assessed expectancy for improvement and its 
relationship to treatment outcome, Arnkoff, Glass, and Shapiro (2002) found support for 
a positive relationship in 12 studies, mixed support in seven studies, and null findings in 
the remaining five studies. Noble, Douglas, and Newman (2001) also reviewed the 
literature and found a curvilinear relationship between expectancy and outcome, where 
individuals with moderate expectations for improvements showed more improvement 
than those with very high or very low expectations. It seems that the relationship between 
expectancy and treatment outcome is not straightforward. As mentioned previously, 
differences in definitions and measures of expectancy, timing of assessments, blinding 
procedures, treatments, and sample characteristics offer some explanation for these 
discrepant findings.  
Most of the research on expectancy in psychotherapy clinical research trials has 
focused on the treatment of anxiety. For example, in a study investigating the efficacy of 
group CBT for the treatment of social phobia, Safren, Heimberg, and Juster (1997) found 
that treatment expectancy, as measured by the Reaction to Treatment Questionnaire 
(RTQ; Holt & Heimberg, 1990), predicted post-treatment severity of social phobia after 
controlling for initial severity of symptoms. The RTQ assesses clients’ confidence that 
treatment will eliminate their social anxiety in specific social situations. Initial RTQ 
ratings were negatively correlated with severity and duration of social anxiety and 
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depressive symptoms. RTQ scores were also correlated with level of education; 
individuals who had completed some postgraduate education had higher expectations for 
improvement than individuals who had not completed high school. One possible 
explanation for this finding is that level of education may be correlated with confidence 
in one’s ability to master cognitive-behavioral techniques and benefit from treatment. In 
addition to predicting a decrease of anxiety symptoms, overall RTQ also predicted 
changes in depressive symptoms. It is possible that expectancy effects may not be limited 
to an individual’s specific expectations (i.e. improvement of anxiety alone), although 
participants’ expectancy for improvement of their depressive symptoms, or improvement 
in general, were not assessed. 
Similarly, Chambless, Tran, and Glass (1997) assessed treatment expectancy 
using a four-item treatment expectancy scale (Borkovec & Nau, 1972) in a sample of 
participants receiving group CBT for social phobia. Participants were administered the 
measure, which included a question about the perceived credibility of CBT, after they 
had received a rationale for the treatment. Consistent with Saffren, Heimberg, and 
Juster’s findings, higher treatment expectancies and the perceived credibility of treatment 
were predictive of improvement on measures of social anxiety. Since depressive 
symptoms were predictive of both poor outcome and lower expectations for 
improvement, the investigators controlled for the overlap of depressive symptoms and 
treatment expectancy.  
Positive findings have also been demonstrated for short-term therapy for speech 
anxiety (Kirsh & Henry, 1977, 1979) and the treatment of specific phobias. Price, 
Anderson, and Heinrich (2008) conducted an analysis using hierarchical linear modeling 
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in a sample of participants receiving either virtual reality exposure (VR) or in vivo 
exposure for flying phobia (Rothbaum, Anderson, Zimand, Hodges, Lang, & Wilson, 
2006). They adapted Borkovec and Nau’s 1972 measure of expectancy to include the 
following three statement ratings: 1) Confidence that therapy would reduce fear of flying-
related symptoms, 2) confidence that therapy would reduce other fears, and 3) how 
logical treatment seemed. Because the three items demonstrated less than satisfactory 
internal consistency, it was decided that the first item would be used alone to measure 
treatment expectancy. Confidence that therapy would reduce fear of flying-related 
symptoms predicted treatment gains made during therapy but not during follow-up. 
However, in a study of participants with panic disorder and agoraphobia 
randomized to alprazolam and exposure (AE), placebo and exposure (PE), alprazolam 
and relaxation (AR), or placebo and relaxation (PR), treatment expectancy did not predict 
treatment outcome (Basoglu, Marks, Swinson, Noshirvani, O’Sullivan, & Koch, 1994). 
Participants were asked to rate their perceived benefit from “psychological treatment” 
and “drug treatment” prior to treatment initiation, but were not asked to differentiate 
between exposure and relaxation training. Additionally, they were not asked to rate their 
perceived benefit from combination treatment, which is important since each participant 
received a combination of pills and psychotherapy. In a follow-up study, higher treatment 
expectations for pharmacotherapy were found to be associated with greater attributions 
for improvement to drug treatment in treatment responders (Basoglu, Marks, Kilic, 
Brewin, & Swinson, 1994). Greater attribution of improvement to medications predicted 
more severe withdrawal effects and a relapse of symptoms during follow-up, although 
treatment expectancy alone did not emerge as a predictor.  
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 Vogel, Hansen, Stiles, and Gotesman (2006) also failed to find a relationship 
between treatment expectancy and outcome in a study investigating the efficacy of CBT 
for Obsessive Compulsive Disorder. In their study, treatment expectancy was assessed on 
a scale from 0-100 with higher scores indicating greater confidence in CBT as a treatment 
for OCD. The investigators found a relationship between positive helping alliance and 
decreased severity of OCD symptoms post-treatment. It may be that expectancy has a 
greater variability of impact due to clients’ presenting concerns/diagnoses (e.g. OCD 
versus social phobia), compared to the therapeutic relationship.  
Relatively fewer studies have been conducted on expectancy and mood disorders. 
Gaudiano and Miller (2006) investigated the role of expectancy on outcome in adults 
treated for bipolar disorder with semi-structured pharmacotherapy with or without family 
psychoeducation group therapy. Utilizing the four-item Credibility and Expectancy Scale 
(CES; e.g. “This treatment will be successful in eliminating symptoms of bipolar 
disorder; Borkovec & Nau, 1972), the investigators found a significant relationship 
between pre-treatment expectancy levels, patient and doctor-rated alliance, and long-term 
outcome in bipolar patients treated with pharmacotherapy for up to 28 months following 
an acute episode of either mania or depression. This study is noteworthy in that the focus 
of the outcome was long-term and investigated the roles of both expectancy and 
therapeutic alliance.  
 Treatment expectancy, but not “global” expectancy (i.e. “How do you think things 
will most likely be this time of year from now?”) also predicted both treatment alliance 
and outcome in the Treatment of Depression Collaborative Research Program (TDCRP) 
funded by the National Institute of Mental Health (Stotsky et al., 1991). The TDCRP 
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compared Interpersonal Therapy (IPT), CBT, imipramine plus clinical management, and 
placebo plus clinical management for the treatment of depression. Meyer and colleagues 
(2002) found that the quality of therapeutic alliance mediated the relationship between 
treatment expectancy and improvement of depressive symptoms in a follow-up analysis. 
They concluded that participants with higher expectancies for improvement were more 
likely to engage in session with their treatment providers, which in turn led to symptom 
reduction.  
The hypothesis that expectancy impacts treatment outcome by increasing 
treatment engagement is consistent with the finding that early homework adherence 
mediated the relationship between overall expectancy and improved outcomes in adults 
treated with group CBT for anxiety (Westra, Marcus, & Dozois, 2007). The investigators 
used the Anxiety Change Expectancy Scale (ACES; Dozois & Estra, 2005) to measure 
expectancy, which asked participants to rate their agreement with statements such as “I 
feel pessimistic that my anxiety problems could ever change for the better.” They found a 
mediation effect for Generalized Anxiety Disorder and Panic Disorder, but not for Social 
Phobia, perhaps due to this latter group’s small sample size and poorer outcome. It is 
unclear if homework completion also mediates the relationship between treatment 
expectancy and outcome. 
In addition to identifying possible mediators between treatment expectancy and 
outcome, attempts have been made to manipulate treatment expectancy in order to 
determine a causal relationship with outcome. Shaw and Blanchard (1983) randomized 
participants to one of three conditions: 1) “positive demand” set, 2) “neutral demand” set, 
and 3) waitlist control. The first two groups received a multi-component stress 
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management program, including psycho-education about stress, relaxation training, and 
cognitive coping strategies. Those randomized to the positive demand set were told that 
the program had been shown to be “very effective,” while those randomized to the 
neutral demand set were told that the treatment was “experimental.” The positive demand 
set had higher expectancies for improvement compared to the other two groups and 
engaged in more home practice (i.e. “homework”) than the neutral demand set. 
Moreover, they had significantly greater reductions in systolic blood pressure reactivity 
post-treatment, as well as greater confidence in their ability to manage stress.  
More recently, Westra and Dozois (2006) conducted a pilot study where 
participants were randomized to receive CBT with or without first undergoing 
motivational interviewing (MI). Participants who received MI reported significantly 
higher expectancy for anxiety control compared to participants who did not receive pre-
treatment MI, and were more likely to complete homework assignments. These 
participants were also more likely to respond to CBT. These two studies, though 
preliminary, suggest that expectancy is 1) capable of being manipulated and 2) may lead 
to improved outcomes by increasing motivation and treatment engagement.  
 
Expectancy in Child and Adolescent Treatment Outcome Research 
 The literature on expectancy and the treatment of children and adolescents with 
mental health problems is extremely limited. Nock and Kazdin (2001) found that 
mothers’ expectancies of improvement for their children with oppositional, aggressive, or 
antisocial behavior problems were predictive of participation in treatment in that mothers 
with either very high or very low expectations were the least likely to drop out of 
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treatment. Children received problem-solving skills training, while parents received 
parent management training. Children’s treatment expectancies were not assessed 
because the researchers believed that parents’ expectations were more important in 
determining treatment outcome. 
More recently, Lewin, Peris, Bergman, McCracken, and Piacentini (in press) 
examined the correlates of parent, child, and therapist treatment expectations in an 
exposure-based treatment study of childhood OCD. The investigators identified 
children’s baseline depressive symptoms, functional impairment, externalizing behavior 
problems, number of comorbid psychiatric disorders, and perceptions of control as 
predictive of treatment expectancy in their sample of 49 youth. OCD severity was not 
correlated with treatment expectancy. Of note, treatment expectancy was positively 
associated with treatment response, homework compliance, and treatment retention in 
this childhood sample.  
Overall, the studies discussed above suggest that treatment expectancy impacts 
treatment outcome for adults with mood and anxiety disorders, perhaps through increased 
engagement with treatment. Less is known about the importance of treatment expectancy 
in children and teens, although the recent study conducted by Lewin, Peris, Bergman, 
McCracken, and Piacentini suggests that treatment expectancy is also important for these 
often combined populations. Given the significant and increasingly recognized mental 
health needs of children and adolescents, further research is warranted in order to better 
understand treatment expectancy and its impact on treatment outcome. 
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The Treatment for Adolescents with Depression Study (TADS) 
The Treatment for Adolescents with Depression Study (TADS) offers a unique 
opportunity to assess outcome expectancy in a multi-site study involving an adolescent 
population, psychotherapy, pharmacotherapy, as well as combination treatment. TADS is 
the first randomized control study to compare the leading treatments for depression in an 
adolescent sample (TADS Team, 2005). Four-hundred and thirty-nine adolescents, ages 
12-17 (inclusive) who met Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition (DSM-IV; APA, 1994) criteria for major depressive disorder (MDD) were 
randomized to receive one of the following four treatments: Fluoxetine (FLX; 10-40 mg), 
CBT, the combination of the two treatments (COMB), and placebo (PBO). 
The initial TADS findings have received considerable attention. At the end of 12 
weeks of treatment, 71.0% of adolescents in COMB, 60.6% in FLX, 43.2% in CBT, and 
34.8% of adolescents randomized to PBO were rated as “very much improved” or “much 
improved” according to the independent evaluator-rated Clinical Global Impressions 
Improvement scores (CGI-I, Guy, 1976; TADS Team, 2004). Teens assigned to COMB 
exhibited the fastest rate of recovery followed by FLX, which outperformed CBT but not 
PBO. No differences were found between CBT and PBO in terms of rate or response or 
percentage of responders. Suicidal thinking improved significantly in all four treatment 
conditions with suicidality improving the most in teens assigned to COMB and the least 
in teens assigned to FLX. Considering both the risks and benefits of treatment, the TADS 
Team concluded that the combination of FLX and CBT is a more effective treatment for 
adolescent depression than either therapy alone.  
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Despite convincing evidence, the “uneven blind” in TADS has been identified as 
a design feature that casts doubt on the strength of this conclusion (Jureidini, Tonkin, & 
Mansfield, 2004). The “uneven blind” refers to the fact that adolescents assigned to either 
CBT or COMB were not blinded to their treatment conditions, unlike adolescents 
assigned to “pills only” (i.e. either FLX or PBO). It has been suggested that this design 
feature generated meaningful differences in adolescents’ expectancy for improvement, 
accounting for COMB’s superior performance (Jureidini, Tonkin, & Mansfield, 2004). 
The untested assumption behind this criticism is that COMB would not outperform the 
other three conditions after controlling for treatment expectancy. Underlying this 
hypothesis is also an argument in favor of common over specific factors. 
Indeed, although blinded independent evaluators were responsible for the main 
outcome ratings in TADS, these evaluators were able to correctly guess teens’ assigned 
treatment conditions at rates greater than expected by chance (25%) for each of these 
treatment conditions at weeks 6 and 12 (Murakami et al., in progress). Additionally, teens 
assigned to FLX or PBO were also able to correctly guess their assigned treatment 
conditions at rates significantly greater than chance (50%) at both time points. While it is 
likely that independent evaluators based their treatment guessing on participants’ 
treatment response, it is unclear how they were able to accurately choose teens’ assigned 
treatment conditions between the three active TADS treatments (COMB, FLX, or CBT). 
Most likely, they also relied on participants’ reported side effects, imperfect blinding 
procedures (e.g. seeing a teen enter a room with a pharmacotherapist), or participant “slip 
ups” (e.g. a participant stating, “I really like my therapist.”) to guess correctly. These 
results suggest that independent evaluators’ and participants’ treatment expectancies may 
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have impacted both independent evaluator ratings (i.e. rater bias) and adolescents’ 
response to treatment, respectively, due to imperfect blinding procedures.  
Consistent with the hypothesis that treatment expectancy accounts for the 
treatment effects found in TADS, Curry and colleagues (2006) identified adolescents’ 
assigned treatment expectancies as a significant predictor of treatment response in a 
thorough investigation of 20+ potential predictors and moderators of treatment outcome 
in TADS. The investigators used a series of GLMs with CGI-I scores (responders versus 
non-responders to treatment) as their outcome variable. Adolescents’ assigned treatment 
expectancy did not emerge as a moderator of treatment; meaning that regardless of 
treatment assignment, higher expectations for improvement were associated with greater 
reductions in depression after 12 weeks of treatment. Younger age, a shorter duration of 
depression, a higher level of functioning, and lower levels of hopelessness and suicidal 
ideation, as well as fewer melancholic features and comorbid diagnoses also emerged as 
predictors of response to treatment.  
Intriguingly, family income level was found to be a moderator of treatment 
outcome; teens from family income levels (>$75,000) responded as well to CBT as 
COMB and FLX. The investigators noted that this finding was not mediated by verbal-
intelligence scores. Severity of depression and the presence of cognitive distortions also 
emerged as moderators of treatment. In regards to severity of depression, adolescents 
with marked to severe depression were as likely to respond to FLX as COMB, whereas 
adolescents with mild to moderate levels of depression were more likely to respond to 
COMB than FLX or CBT alone.  
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The identification of predictors and moderators of treatment is an important step 
in answering Gordon Paul’s (1967) often quoted and reverberating question: “What 
treatment, by whom, is most effective for this individual with that specific problem, and 
under which set of circumstances?” The current study builds on Curry and colleagues’ 
findings with a closer examination of treatment expectancy in TADS. The study also 
seeks to clarify whether or not treatment expectancy accounts for the treatment 
differences initially reported by the TADS Team (TADS Team, 2004).   
 
Study Aims and Hypotheses 
Aim 1 
The first aim of the current study is to investigate the relationships between 
treatment expectancy and adolescent demographic variables (e.g. gender, ethnicity, and 
family income levels), symptom characteristics (e.g. depression severity and chronicity, 
hopelessness, and suicidality), and treatment site in TADS. Participants in the study 
indicated their treatment expectations for COMB, CBT, and medication only (three 
separate ratings) prior to treatment randomization. However, only teens’ assigned 
treatment expectancies (one of the three ratings) were examined in the Curry et al. paper. 
I will examine each of these three ratings separately for aim 1, as well as a previously 
unexamined measure, the CBT Rationale Acceptance and Expectation for Improvement 
(C-RAEI) form, which was specifically designed for TADS and administered to 
adolescents receiving CBT and COMB during their second CBT session.  
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Hypothesis 1.1 
It is hypothesized that teens will have higher expectations for COMB compared to 
CBT and FLX. This is expected to be true both within (i.e. when comparing teens’ ratings 
for COMB, CBT, and medication only for the whole sample) and between subjects (i.e. 
when comparing the teens’ assigned treatment ratings. 
Hypothesis 1.2 
Teens with family income levels at or above $75,000 will endorse higher 
expectancies for CBT than teens with family income levels below $75,000. 
Understanding the relationship between treatment expectancy and family income level 
may help to clarify the relationship between family income level and response to CBT. 
Hypothesis 1.3 
Severity markers of illness, including severity and chronicity of depression, the 
presence of comorbid disorders, hopelessness, and suicidality will predict lower treatment 
expectations across treatment modalities.  
Hypothesis 1.4 
Treatment expectancy will differ by treatment site. This hypothesis is based on 
Simons and colleagues’ (in preparation) findings that site had a significant impact on 
outcome. The thirteen sites in TADS differed by location, type of setting (e.g. University 
versus medical center), sample characteristics, and study staff characteristics (e.g. 
experience providing CBT), which likely impacted participants’ treatment expectations.   
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Aim 2 
The second aim of the current study is to replicate and extend Curry and 
colleagues’ finding that assigned treatment expectancy predicts but does not moderate 
treatment outcome. In addition to the clinician-rated CGI-I, the primary outcome in 
TADS (the CDRS-R) will be used as a measure of outcome, as well as the self-rated 
Reynolds Adolescent Depression Scale (RADS; Reynolds, 1987). The RADS will be 
used as a primary outcome measure, since one might suspect that treatment expectancy 
would have more of an impact on a self-rated measure of depression as opposed to a 
clinician-rated measure. While Curry and colleagues used generalized linear model 
(GLM) to investigate potential moderators and predictors of treatment in TADS, random 
coefficient regression models (RRMs) will be used to replicate the investigators’ 
findings. RRM is the preferred method for investigating longitudinal data given its ability 
to handle missing and nested data, and is consistent with the primary TADS analysis 
(TADS Team, 2004). RRM was not used in the Curry et al. paper due to the high number 
of potential predictors and/or moderators under investigation, and concerns over model 
convergence. 
Hypothesis 2.1 
Treatment expectancy will predict but not moderate treatment outcome. This is 
expected for both clinician-rated (CDRS-R and CGI-I) and self-rated (RADS) outcome 
measures. 
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Aim 3 
The third aim of the study is to investigate whether or not treatment expectancy 
predicts treatment completion. Lewin, Peris, Bergman, McCracken, and Piacentini (in 
press) found that treatment expectancy predicted study retention in their study of CBT for 
the treatment of childhood OCD. For the most part, however, treatment retention has 
been largely ignored in the expectancy literature. 
Hypothesis 3.1 
It is hypothesized that treatment expectancy will predict completer status (y/n), 
where teens with higher expectations for improvement will be more likely to remain in 
treatment for the full 12 weeks than those with lower expectations for improvement. 
Aim 4 
Given that research suggests that the placebo effect is less likely to occur in 
severe depression (Shapiro & Shapiro, 1997; Khan et al., 2002; Wilcox et al., 1992; 
Fairchild et al., 1986), the forth aim of the current study is to investigate whether or not 
severity of depression moderates the impact of treatment expectancy on outcome in 
TADS.  
Hypothesis 4.1 
It is hypothesized that severity of depression will moderate the relationship 
between treatment expectancy and treatment outcome in TADS, where treatment 
expectancy will have more of an impact on treatment outcome for teens with a mild-
moderate level of depression compared to teens with a severe level of depression. 
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Aim 5 
The fifth aim of the current study is to investigate whether or not treatment 
expectancy can account of COMB’s superior performance in TADS. As mentioned 
previously, TADS has been criticized for its “uneven” blind. Adolescents randomized to 
CBT and COMB were cognizant of their assigned treatment conditions, which may have 
impacted their treatment response. However, it is also possible that COMB will continue 
to outperform the other three TADS treatments after controlling for the effects of 
treatment expectancy. 
Hypothesis 5.1 
It is hypothesized that COMB will continue to outperform the other three 
treatment conditions after controlling for treatment expectancy. Lambert’s (1992) four-
factor model posits that expectancy and specific treatment effects determine treatment 
outcome at equivalent rates (approximately 15%). Therefore, I would expect treatment to 
predict outcome even after controlling for treatment expectancy. 
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CHAPTER II 
METHOD 
Participants 
Four hundred and thirty-nine adolescents (M = 14.6 years, SD = 1.54 years) who 
met eligibility criteria for TADS were enrolled in one of the 13 academic and community 
sites across the United States. Participants were recruited through radio, television, and 
newspaper advertisements, as well as through referrals from primary care physicians, 
mental health providers, school personnel, and the juvenile justice system. In order to 
participate in the study, adolescents were required to meet criteria for a primary diagnosis 
of major depressive disorder according to the DSM-IV as assessed by the Schedule for 
Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime 
Version (K-SADS-PL; Kaufman et al., 1997). Further inclusion criteria included at least 
a moderate level of depression based on a Child Depression Rating Scale-Revised 
(CDRS-R; Poznanski & Mokros, 1996) total score of > 45 at baseline, a current episode 
of depression lasting at least six weeks, and impairment in at least two out of three major 
contexts including home, school, and peer relationships.  
Adolescents who met criteria for a comorbid Axis I diagnosis were included in 
the study with the exceptions of bipolar disorder, current substance abuse/dependence, 
severe conduct disorder, pervasive developmental disorders, and thought disorders. 
Adolescents were also excluded from the study if they were actively suicidal/homicidal 
and if they had not responded to two previous trials of selective serotonin reuptake 
inhibitors or a course of CBT for depression. Concurrent pharmacotherapy or 
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psychotherapy was not permitted during the study. Additionally, a full-scale IQ of at least 
80 and the availability of a participating English-speaking parent or family member were 
required. A detailed description of the full TADS sample has been published elsewhere 
(TADS Team, 2005).  
 Of the 439 adolescents who enrolled in TADS, 403 adolescents (Mage=14.62, 
SD=1.56) filled out the Treatment Expectancy for Adolescents (TEA) form prior to 
treatment randomization and were included in the current study. Of the 403 adolescents, 
43.9 % (n=177) were male and 56.1 % (n=226), female. The majority of participants 
identified their race/ethnicity as Caucasian (n=298, 73.9%), African American (n=48, 
11.9%), or Hispanic, White (n=29, 7.2%). Eight participants (2%) selected Hispanic, 
Black, while the remaining participants selected Asian American (n=3, .7%), Pacific 
Islander (n=2, .5%), or other (n=15, 3.7%) as their race/ethnicity. The subsample of 
adolescents included in this study had a mean CDRS-R score of 60.06 (SD=10.33), 
which suggests a moderate level of depression. The current subsample did not differ from 
the full TADS sample in terms of age or severity of depression (p>.05).  
 
Study Procedures 
 Adolescents were screened for participation in TADS in a three-stage process 
(Gates A-C). At Gate A, adolescents were assessed for eligibility using a brief screening 
measure by phone or in person. Adolescents and their parents were given an explanation 
of the study, including a brief description of each of the TADS treatments (typically no 
more than a few sentences, i.e. “CBT is a type of psychotherapy that has been shown to 
be effective for the treatment of depression”), and provided informed consent at Gate B. 
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In addition, adolescents were assessed using the K-SADS-PL during this visit. The 
majority of self-report forms, including the TEA, were filled out at Gate C prior to 
randomization. After confirmation of eligibility, teens were randomized to receive FLX, 
CBT, COMB, or PBO on a 1:1:1:1 allocation ratio with site and gender used as 
stratification variables. Subsequently, teens assigned to CBT and COMB were informed 
of their particular treatment assignments, while teens assigned to FLX and PBO were told 
they had been assigned to "pills only." Thus, only teens assigned to FLX or PBO were 
blinded to their treatment conditions. Following Gate C, adolescents entered into the 
acute phase of TADS (Stage I), which consisted of twelve weeks of treatment. Stage II 
(consolidation) consisted of six weeks of follow-up, while Stage III (continuation) and 
Stage IV (naturalistic) consisted of 18 weeks and one year of follow-up, respectively. The 
current study focuses on the results of Stage I, or the first 12 weeks of treatment. 
 During Stage I, participants randomized to FLX or PBO conditions met with their 
assigned pharmacotherapist for 20-30 minutes six times over 12 weeks. Adolescents were 
started on 10 mg/day, which could be raised up to 40 mg by week eight based on 
adolescents’ treatment response and their tolerability to pills. During the acute phase of 
the study, participants randomized to the CBT condition received up to 15 sessions of 
psychotherapy lasting between 50 and 60 minutes each. These sessions included 
psychoeducation about depression, as well as manualized cognitive-behavioral 
techniques designed to increase pleasant activities and restructure dysfunctional thoughts. 
The rationale behind TADS CBT is that depression is either caused and/or maintained by 
a lack of positively reinforcing behavior and the presence of depressive thinking (Clark, 
Lewinson, & Hops, 1990; Brent & Poling, 1997). Additionally, two sessions were 
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devoted to psychoeducation for parents during weeks one through six, and one to three 
conjoint family sessions could be substituted for individual therapy sessions with teens 
between weeks seven and 12. COMB treatment included all of the elements of both FLX 
and CBT.  
 Independent evaluators, blinded to teens’ assigned treatment conditions, 
conducted the outcome assessments in TADS in order to minimize experimenter bias. At 
every assessment point, study coordinators reminded adolescents and their parents not to 
disclose information (e.g. the names of teens’ CBT therapists or pharmacotherapists) that 
might reveal teens’ assigned treatment conditions to their independent evaluators. Only in 
cases of emergency, such as sudden worsening of suicidality, were adolescents assigned 
to FLX/PBO and their pharmacotherapists informed of teens’ actual treatment 
assignments.  
  
Baseline Measures 
Demographic Information 
Demographic information, including a participant’s age, sex, race/ethnicity, and 
family income level, was collected prior to initiation of treatment. Participants’ age, sex, 
and race/ethnicity were assessed through self-report. Gross family income over the past 
year was obtained through a version of the Child and Adolescent Services Assessment 
(CASA; Burnds, Anold, Costello, & Ascher, 1999) conducted by the study coordinator 
with the teen’s parent(s). The CASA categorizes income from less than $5,000 to greater 
than $200,000. Previously, the original 12 categories were collapsed to the following five 
categories: $0-$19,999, $20,000-$39,999, $40,000-$74,999, $75,000-$99,999, and 
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>$99,999 based on the sample distribution of the original TADS sample. Because Curry 
and colleagues identified family income level as a moderator of treatment outcome in 
TADS, where teens with higher family income (> $75,000) were more likely to respond 
to CBT, a separate categorical variable will be created for income based on this cutoff.     
 
Depression Severity, Duration, and Comorbidity 
Clinical Global Impression-Severity and Improvement Scales 
Severity of depression was determined according to the clinician-administered 
Clinical Global Impressions-Severity Scale (CGI-S; Guy, 1976). The CGI-S is based on a 
7-point rating of depression severity, where a score of one indicates "Normal, not 
mentally ill", and a score of seven indicates "Among the most extremely mentally ill." 
The CGI-S is among the most widely used brief assessment measures in psychiatry and is 
a standard used in clinical research trials for children, adolescents, and adults. In order to 
insure inter-rater reliability, TADS Independent Evaluator and Clinician Assessment 
Manuals were developed, which specify rating guidelines for the CGI-S and Clinical 
Global Impressions-Improvement Scale (CGI-I; Guy, 1976). Additionally, independent 
evaluators were required to submit their first two interviews to the coordinating site for 
evaluation of quality of administration and rating accuracy.  
 
Schedule for Affective Disorder and Schizophrenia for School-Age Children 
  
The duration of the current depressive episode and the presence of comorbid 
mental health diagnoses were determined by the independent evaluator based on the 
Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present 
and Lifetime (K-SADS-PL; Kaufman et al., 1997), an extensively used semi-structured 
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interview that assesses for Axis I disorders included in the DSM-IV-R, including mood, 
anxiety, attention-deficit/ hyperactivity, disruptive behavior, eating, elimination, 
substance-related, and psychotic disorders. Independent evaluators interviewed both the 
adolescent and the parent(s), incorporating both sources of information. The K-SADS-PL 
has high interrater reliability (93-100%) across diagnoses and excellent test-retest 
reliability for major depression (.90), in particular. 
In the full TADS sample, the presence of a comorbid anxiety disorder and the 
number of comorbid disorders both emerged as predictors of treatment response (Curry et 
al., 2006). Adolescents with a comorbid anxiety disorder (social anxiety disorder, 
separation anxiety disorder, generalized anxiety disorder, panic disorder, agoraphobia, or 
posttraumatic stress disorder), as well as adolescents with a greater number of comorbid 
disorders, were less likely to respond to treatment. Both of these comorbidity groupings 
and their relationship to treatment expectancy will be examined in the current study.  
 
Expectancy-Related Measures 
Treatment Expectancy for Adolescents (TEA) Form 
Prior to treatment randomization, adolescents filled out the Treatment Expectancy 
for Adolescents (TEA) form, where they rated to what extent they thought their 
"depression problems" would improve with COMB, CBT, and "medication only." Since 
there are no measures of psychometrically validated treatment expectancy measures for 
children and adolescents with depression, the TEA was designed specifically for TADS. 
The TEA is based on a Likert scale with one indicating the most benefit from treatment 
(“very much improved”) and seven indicating the least benefit/most harm from treatment 
  
35 
 
(“very much worse”; see Appendix A). Only after filling out the TEA were adolescents 
randomized to one of the four treatment conditions in TADS. 
Assigned Treatment Expectancy (Assigned TE) 
Adolescents’ assigned TE ratings were identified as the ratings that they selected 
on the TEA for their randomized treatment arms. For example, if a teen selected a rating 
of 1 (“very much improved”) for COMB, 2 (“much improved) for CBT, and 3 (“much 
improved”) for medication alone, and then was subsequently assigned to CBT, this 
participant had an assigned treatment expectancy of 2. For teens assigned to FLX or 
PBO, their treatment expectancy ratings were considered to be their expectancy ratings 
for treatment with medication only, since these adolescents were blinded to their 
conditions and expectancy for improvement with PBO was not assessed. Thus, each 
adolescent had an expectancy rating for COMB, CBT, and medication only; each 
adolescent also had an assigned TE rating based on the TEA for their assigned treatment. 
 
CBT Rationale Acceptance and Expectation for Improvement (CBT-RAEI)  
 
Adolescents randomized to receive CBT or COMB also filled out the CBT 
Rationale Acceptance and Expectation for Improvement (C-RAEI) form during their 
second CBT session after learning more about the rationale for CBT and what treatment 
entails. The C-RAEI, also designed specifically for TADS, consists of six questions (see 
Appendix B), three of which pertain to acceptance of treatment rationale (“The 
therapist’s explanation of what cognitive behavior therapy is made sense to me.”), and 
three of which pertain to treatment expectancy (“I expect to get better or become less 
depressed through this program.”). Individuals were asked to rate each of the six 
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statements on a scale from one ("strongly disagree") to five ("strongly agree"). A total of 
192 TADS participants filled out the C-RAEI. A reliability analysis revealed excellent 
internal consistency (α = of .918) of the measure. 
 
Hopelessness 
The Beck Hopelessness Scale (BHS; Beck & Steer, 1993) is a 20-item, self-report 
measure with high internal consistency (α = .82 to .93) based on a T/F format with a 
maximum score of 20, where higher scores indicate greater levels of hopelessness. 
Sample items include the following T/F statements: "I look forward to the future with 
hope and enthusiasm," and "All I can see ahead of me is unpleasantness rather than 
pleasantness." Total BHS scores were found to predict treatment response in TADS 
(Curry et al., 2006).  
 
Suicidal Ideation 
The Suicididal Ideation Questionnaire-Jr. High Version (SIQ-Jr; Reynolds, 1987) 
was used to determined adolescents' severity of suicidal ideation. The SIQ-Jr is composed 
of 15 items with each item rated on a Likert scale from zero ("I never had this thought") 
to six ["(I had this thought) almost every day"] within the past month (e.g. "I thought I 
would be better off if I was not alive."). An aggregate score of 31 required the assessment 
for further suicidal risk in TADS. The measure has been shown to have high internal 
consistency (α = .94) and moderate test-retest reliability in adolescents. Total SIQ-Jr 
scores also emerged as a predictor of treatment response in TADS (Curry et al., 2006). 
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Outcome Measures 
Clinician-Rated Measures 
Children's Depression rating Scale-Revised (Poznanski & Mokros 1995) 
The Children’s Depression Rating Scale-Revised (CDRS-R) is a 17-item, 
clinician-administered rating scale that is commonly used to assess the severity of 
depression in children and adolescents based on the DSM-IV-R, and is one of two 
measures chosen a priori as the primary outcome measure for TADS. Each item is rated 
on a seven-point scale for a total score from 17 to 113, with higher scores indicating 
greater depression severity. The 17 items cover distinct areas characteristic of depression, 
including social withdrawal, hypoactivity, appetite and sleep disturbance, excessive 
fatigue, difficulty having fun, irritability, low self-esteem, morbid/suicidal ideas, 
impaired schoolwork, physical complaints, excessive guilt and weeping, listless speech, 
depressed facial affect, and depressed mood. Previous studies suggest that the CDRS-R 
has high internal consistency (α = .85), interrater reliability (r=.92), and test-retest 
reliability (r = .78; Poznanski & Mokros, 1996). Independent evaluators administered the 
CDRS-R at baseline, week six, and week 12.  
 
Clinical Global Impressions Improvement (Guy, 1976) 
The Clinical Global Impressions Improvement (CGI-I) is the second primary 
outcome measure chosen a priori in TADS. Independent evaluators were instructed to 
review the CDRS-R and the CGI-S from the adolescent’s baseline evaluation, as well as 
assessment information from the previous assessment visit in order to remind themselves 
of the adolescent’s baseline presentation and trajectory of symptom improvement. This 
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information enabled independent evaluators to select the most appropriate CGI-I rating 
from one (“very much improved”) to seven (“very much worse”) with four indicating “no 
change.” In TADS, adolescents who received “very much improved” or “much 
improved” CGI-I ratings were considered responders to treatment, while adolescents who 
received “minimally improved” to “very much worse” scores were considered non-
responders to treatment. The CGI-I was administered at week six and week 12 by 
independent evaluators. 
 
Treatment Completion 
 
 Adolescents were categorized into treatment completers or non-completers based 
on whether or not they completed the acute phase of TADS (12 weeks of acute 
treatment). 
 
Self-Rated Measure 
 
Reynolds Adolescent Depression Scale (Reynolds, 1987) 
The Reynolds Adolescent Depression Scale (RADS) is a self-report measure of 
depression severity in teens and consists of 30-items, each rated on a Likert scale from 
one (“almost never”) to four (“most of the time”).  Sample items include, "I feel sad," "I 
feel like crying," and "I feel no one cares about me," which fall under one of four basic 
dimensions of depression: dysphoric mood, anhedonia/negative affect, somatic 
symptoms, and negative self-evaluation. Total scores range from 30-120 with higher 
scores indicating greater depression severity. The RADS has demonstrated high internal 
consistency (α = .92) and test-retest reliability at six weeks (r=.80) and three months 
(r=.79). Concurrent validity has also been demonstrated with the Hamilton Rating Scale 
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(Hamilton, 1967). TADS adolescents filled out the RADS at baseline, week six, and 
week 12. 
Statistical Methods 
 
 All statistical analyses were conducted using SPSS version 19.0. 
 
Aim 1: Investigate the relationship between treatment expectancy, demographic 
variables, and clinical variables (e.g. hopelessness) 
Pearson’s correlations were calculated to measure the strength of the relationship 
between treatment expectancy for COMB, CBT, and medication only and the following 
continuous dependent variables: total C-RAEI scores, age, severity of depression (as 
measured by the CDRS-R), chronicity of depression, suicidality, hopelessness, and the 
number of participants’ comorbid disorders. One-way between subjects analysis of 
variances (ANOVAs) were used to assess for differences in treatment expectancy based 
on categorical variables, including race/ethnicity, family income levels (based on five 
categories), severity of depression (as measured by the CGS), and the presence of a co-
occurring anxiety disorder. Independent samples t-test were used to test for differences in 
treatment expectancy based on gender and a dichotomized family income level (<$75,000 
and >$75,000).  
 
Aim 2: Replicate and extend Curry et al.’s finding that assigned TE predicts but 
does not moderate treatment outcome  
A random coefficients regression model (RRM) with fixed (treatment, time, site, 
assigned TE, and their 2-way and 3-way interactions) and random (subject and subject by 
time) effects was conducted with the CDRS-R as the outcome variable. A similar RRM 
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analysis was conducted with the RADS replacing the CDRS-R as the outcome variable. 
Random regression has been identified as an ideal approach to data analysis of 
continuous repeated measures with missing data, since it permits estimation of changes 
for missing data on both a participant and population level without using last observation 
carried forward (Guerorguieva & Krystal, 2004; Weinfert, 2000; Brown, 1999) or 
listwise deletion, and is consistent with the main analysis in TADS (TADS Team, 2004). 
RRM is consistent with an intent-to-treat analysis, since all randomized participants, 
regardless of their treatment assignment and adherence to protocol (e.g. missed 
appointments, percentage of homework completed, etc.) are included in the analysis.  
The hypothesis that assigned TE predicts but does not moderate treatment 
outcome is supported if there is a main effect for assigned TE and there are no interaction 
effects with treatment or treatment by time. Table 1 lists the fixed and random effects that 
were included in the initial model (the natural log of time was used instead of linear time, 
which is consistent with the primary TADS analyses). Non-significant interaction effects 
were taken out of the final RRM. Interactions with site were not included in the model 
since they were not significant in the initial model and did not affect study results (TADS 
Team, 2004).  
 
Table 1. Fixed and Random Effects Included in the Initial RRM for Aim 2 
            
Fixed Effects     Random Effects   
Treatment     Subject 
Time     Subject*Time 
Site     
Assigned TE 
Treatment*Time 
Treatment*Assigned TE 
Treatment*Assigned TE*Time 
  
41 
 
Additionally, a first-order autoregressive covariance structure was specified in the 
model, since it accounts for the fact that measurements taken closer in time tend to be 
more highly correlated with each other than measurements taken farther apart in time. A 
first-order autoregressive covariance structure has been suggested as the preferred 
covariance structure in linear mixed models for studies that include repeated 
measurements over time (Neri, Kraemer, Noda, & Yung, 2005). 
Consistent with the initial TADS analyses (JAMA, 2004), logistic regression with 
last observation carried forward (LOCF) was used to determine if assigned TE predicts 
responder status (yes/no) according to the CGI-I. In the full sample, the TADS Team 
found a main effect of treatment (Wald χ2=33.9, p=.001) with planned pairwise contrasts 
demonstrating that COMB (p=.001) and FLX (p=.001) but not CBT (p=.20), 
outperformed PBO. COMB (p=.001) and FLX (p=.001) also outperformed CBT in the 
full sample; the two treatments did not differ from each other (p=.11).  
 RRM and logistic regression were used with total C-RAEI scores in place of 
assigned TE for the subsample of teens treated with CBT or COMB.  RRM was also used 
with the CDRS-R and the RADS as continuous outcome variables, while logistic 
regression was used with the CGI-I as a categorical outcome variable. 
 
Aim 3: Investigate whether or not assigned TE and C-RAIE scores predict 
treatment retention  
A logistic regression was conducted to determine if assigned TE predicts 
completer status (yes/no). Again, fixed effects included treatment, time, site, assigned 
TE, and their 2-way and 3-way interactions (excluding site interactions). Identical 
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analyses were conducted with total C-RAEI scores in place of assigned TE scores for 
teens assigned to CBT or COMB.   
 
Aim 4: Investigate whether or not severity of depression affects the impact of 
assigned TE (and possibly the C-RAEI) on outcome in TADS  
Adolescents were categorized into either mild-moderate or severe depression 
based on their initial CGI-S scores. Adolescents with scores of three (“mildly ill”) or four 
(“moderately ill”) were included in the mild-moderate depression severity category, 
while adolescents with scores of five (“markedly ill”), six (“severely ill”) or seven 
(“among the most extremely ill patients”) were categorized as severely ill. 
A random coefficients regression model with fixed (treatment, time, site, assigned 
TE, depression severity, and their 2-way and 3-way interactions) and random (subject and 
subject by time) effects was run with the CDRS-R as the outcome variable, followed by 
the RADS. The hypothesis that depression severity moderates the effect of treatment 
expectancy on outcome is supported if there is a significant interaction effect between 
assigned TE and depression severity, or if there is a three-way interaction with these two 
variables and time. Logistic regression was used with CGI-I as the outcome variable with 
identical fixed effects for categorical variables with continuous variables included as 
covariates. RRM and logistic regression were also used with total C-RAEI scores in place 
of assigned TE for the subsample of teens treated with CBT or COMB. Table 2 lists the 
fixed and random effects that will be included in the initial model for the purpose of aim 
4. 
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Table 2. Fixed and Random Effects Included in the Initial RRM for Aim 4 
            
Fixed Effects     Random Effects   
Treatment     Subject 
Time     Subject*Time 
Site     
Assigned TE 
Severity of depression  
Treatment*Time 
Treatment*Severity of depression 
Assigned TE*Severity of depression 
Assigned TE*Severity of depression*Time 
 
Aim 5: Investigate whether or not assigned TE (and possibly the C-RAIE) can 
account of COMB’s superior performance in TADS.  
This hypothesis is supported if treatment by time is no longer significant in the 
RRM when treatment expectancy is included as a fixed effect. In the primary TADS 
analysis, treatment by time emerged as significant with subsequent contrasts revealing 
that COMB outperformed the other three treatments. I first replicated this analysis with 
the subsample of teens included in this study before including treatment expectancy and 
its interaction terms as fixed effects. Separate analyses were then run with CDRS-R, 
RADS, and CGI-I as outcome variables, the latter requiring the use of logistic regression.  
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CHAPTER III 
RESULTS 
 
Hypothesis 1.1 
 
Prior to treatment randomization, 403 adolescents filled out the TEA, indicating 
their expectations for improvement with COMB, CBT, and medication only. These 
adolescents had the highest expectations for improvement with COMB (M=1.99, 
SD=1.01) followed by CBT (M=2.66, SD=.96) and medication only (M=2.54, SD=1.01) 
with lower scores indicating higher treatment expectancies. A repeated measures 
ANOVA revealed significant differences [F(1.73,690.40)=83.95, p<.001, ηp2=.04] with 
Huyn Feldt correction. Pairwise comparisons revealed higher expectations for 
improvement with COMB compared to CBT (p<.001) and medication only (p<.001); no 
significant differences in expectancy were found between the latter two treatments.  
Similarly, a one-way between-subjects ANOVA revealed differences in 
adolescents’ assigned TEs [F(3,399)=9.53, p<.001, ηp2=.067]. Posthoc analysis using 
Tukey’s HSD demonstrated that teens assigned to COMB had higher assigned treatment 
expectancies than teens assigned to CBT (p<.001), FLX (p<.001) and PBO (p=.002). 
Table 3 lists the frequency of assigned TEs for each of the four treatment conditions. 
Only one participant assigned to FLX (.9%), two assigned to CBT (1.8%), two assigned 
to COMB (1.9%), and one assigned to PBO (.9%) believed their depression problems 
would worsen with treatment; these teens are not included in Table 3. As seen in the 
table, a large percentage of teens (43.6%) assigned to COMB believed their depression 
problems would be “very much improved” in comparison to teens assigned to CBT 
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(9.8%), FLX (11.1%), and PBO (14.9%). The majority of teens in each treatment group 
expected to improve at least minimally with their treatment assignment.  
  
Table 3. Assigned TE Scores by Randomized Treatment Group 
____________________________________________________________________ 
    1          2            3       4           
                 “very much   “much    “minimally       “not changed”   
                   improved” improved”    “improved”       
            n(%)     n(%)          n(%)     n(%)_________ 
COMB        44(43.6%) 33(32.7%)     18(17.8%)              4(4.0%) 
CBT        10(9.8%)              41(40.2%)     37(36.3%)           12(11.8%) 
FLX        11(11.1%)            37(37.4%)     39(39.4%)           11(11.1%) 
PBO           15(14.9%) 42(41.6%)     35(34.7%)             8(7.9%) 
 
Table 4 includes the means, standard deviations, and the results of the one-way 
between subjects ANOVAs for selected baseline variables by treatment group. Prior to 
initiation of treatment, no significant differences were found between the four treatment 
groups in terms of participants’ mean age, duration of their current depressive episode, 
number of comorbid disorders, or scores on the C-RAEI, CDRS-R, RADS, and SIQ. The 
four treatment groups differed in their baseline hopelessness scores [F(3,396)=3.53, 
p=.015, ηp2=.026] in that teens assigned to PBO had higher BHS scores than participants 
assigned to CBT (p=.024) and FLX (p=.029), but not COMB (p=.30). Curry et al. (2006) 
found that adolescents assigned to PBO had higher levels of hopelessness than 
adolescents assigned to the remaining treatment groups in the full TADS sample. 
Differences in treatment expectations for COMB, CBT, and medication only 
based on adolescents’ demographic variables were also investigated. An independent 
samples t-test indicated that females were more likely than males to endorse higher 
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Table 4. Baseline Characteristics by Treatment Group 
______________________________________________________________________________________________ 
Variable                          COMB                  CBT  FLX  PBO  Total                 P-Value            
                                        n=101                  n=102                  n=99               n=101              n=403 
                                        M(SD)                 M(SD)                 M(SD)             M(SD)             M(SD)_________________  
   
Age    14.65(1.50)       14.72(1.51)      14.61(1.56)       14.51(1.68)     14.62(1.56)            .83 
 
Assigned TE                1.92(1.13)            2.56(.90)          2.54(.87)          2.41(.95)          2.35(1.00)          <.001 
 
*C-RAEI                     24.90(5.81)          23.62(5.62)                                                         24.23(5.74)           .18 
 
CDRS-R                      60.31(11.42)         59.45(9.01)     59.20(10.21)    61.28(10.56)     60.06(10.33)          .48 
 
RADS                          79.41(13.78)         78.92(15.04)   77.09(14.62)    81.22(14.00)     79.16(14.39)          .25 
 
BHS                9.85(5.55)             9.04(5.62)        9.07(5.30)      11.23(5.41)        9.80(5.52)             .015 
 
SIQ                              26.54(24.11)         21.93(21.06)    20.86(18.41)    23.91(21.49)    23.32(21.40)          .25 
 
Duration of CDE**     82.13(95.78)     76.12(71.42)    68.66(83.98)     64.08(69.39)    72.77(80.80)    .40 
 
# of comorbid                 .79(.99)                 .76(.91)            .70(1.10)         .78(1.05)          .76(1.01)              .91 
disorders_______________________________________________________________________________________ 
*Only participants assigned to CBT or COMB completed the C-RAEI. 
**Duration of current depressive episode (in weeks)
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expectations for improvement with COMB [t(397)=2.15, p=.03, d=.22], adjusting for 
inequality of variances. Male and female participants did not differ in their expectations 
for improvement with CBT [t(397)=-.339, p=.74] or with medication only [t(400)=1.10, 
p=.27]. Table 5 includes the means and standard deviations of the expectancy ratings for 
the three active treatment groups separated by demographic information. No significant 
effects of race/ethnicity were found. 
 
Table 5. Treatment Expectancy Ratings for COMB, CBT, and Medication Only Based on 
Demographic Variables 
______________________________________________________________________ 
           TE for     TE for  TE for 
Demographic variable          n(%)            COMB      CBT     Medication Only   
                                                       M(SD)     M(SD)            M(SD)_____ 
Gender         
    Male                 177(43.9%)      2.11(1.17)        2.65(.98)             2.60(1.07) 
    Female      226(56.1%)      1.89(.85)          2.68(.95)          2.49(.95) 
Race/ethnicity 
    European American    298(73.9%)       1.93(.89)         2.68(.93)             2.50(.91) 
    African American       48(11.9%)       2.06(1.12)       2.51(1.08)           2.53(.98) 
    Hispanic, Black               8(2.0%)         2.38(2.13)       2.75(1.83)           2.88(1.89) 
    Hispanic, White             29(7.2%)        2.03(1.18)       2.66(.90)             2.62(1.18) 
    Asian American               3(.7%)          2.67(1.16)       2.33(1.16)           3.33(3.22) 
    Pacific Islander                2(.5%)          2.00(1.41)       2.00(.00)             2.50(2.12) 
    Other                             15(3.7%)         2.50(1.45)       3.00(.56)             2.87(1.25) 
Family income 
    $0 - $19,999                 45(11.2%)       1.96(.93)           2.56(.76)            2.42(.89)  
    $20,000 - $39,999        98(24.3%)       2.28(1.21)         3.03(1.12)          2.71(1.02)  
    $40,000 - $74,999      134(33.3%)       1.92(.98)           2.61(.93)            2.47(1.03)  
    $75,000 - $99,999        41(10.2%)       1.59(.67)           2.37(.83)            2.59(.92)  
    Over $99,999               54(13.4%)       2.07(.78)           2.56(.86)             2.57(.92) 
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Hypothesis 1.2 
Treatment expectancies were found to differ based on family income levels for 
CBT [F(4,364)=5.09, p<.001, ηp2=.053] and COMB [F(4,365)=4.03, p=.003, ηp2=.042], 
but not for medication only [F(4,366)=1.08, p=.367]. Posthoc analysis using Tukey’s 
HSD indicated that teens with family income levels from $20,000-$39,999 had lower 
expectations for CBT than teens with family income levels from $40,000-$74,999 
(p=.009), $75,000 - $99,999 (p=.002), and over $99,999 (p=.033). Teens with family 
income levels from $20,000-$39,999 also had lower expectations for improvement with 
COMB than teens with family income levels from $40,000-$74,999 (p=.045), and from 
$75,000-$99,999 (p=.002), but not when compared to teens with family income levels 
equal to or above $99,999 (p=.75).  
Independent samples t-tests subsequently showed that adolescents with family 
income levels below $75,000 had lower expectations for improvement with CBT 
compared to adolescents with family income levels at or above $75,000 [t(368)=2.38, 
p=.018, d=.30], which was not the case for COMB [t(368)=1.83, p=.069], or medication 
only [t(369)=-.27, p=.79], where no differences were found between the two collapsed 
family income groups.                  
 
Hypothesis 1.3 
The hypothesis that difference severity markers of illness, including severity and 
chronicity of depression, hopelessness, suicidality, and the presence of comorbid 
disorders, would be associated with lower treatment expectations across treatment 
modalities was partially supported, as outlined below.  
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Severity of Depression 
Depression severity was not correlated with treatment expectancy for CBT, 
COMB, or medication only (see Table 6) based on the CDRS-R. Nor was it correlated 
with the C-RAEI. Adolescents’ self-rated depression scores (i.e. RADS scores) were 
found to be correlated with their expectations for improvement with COMB (p=.014); as 
participants’ self-rated depression scores increased, so did their expectations for COMB 
treatment.  
Differences in expectations for improvement with CBT were found based on the 
CGI-S using a one-way between subjects ANOVA [F(4,395)=2.50, p=.042, ηp2=.025], 
but not for COMB [F(4,394)=.88, p=.48], or medication only [F(4,397)=.382, p=.82]. 
Post hoc analysis with Tukey’s HSD demonstrated that teens categorized as “moderately 
mentally ill” had higher expectations for CBT (M=2.49, SD=.824) than teens categorized 
as “markedly mentally ill” (M=2.81, SD=1.09; p=.022). The mean scores for each of the 
severity groups in the TADS sample are illustrated in Figure 1 beginning with group 3 
(“mildly mentally ill”) up until group 7 (“among the most extremely mentally ill”). 
Groups 1 (“normal, not mentally ill”) and 2 (“borderline mentally ill”) were not 
represented in the TADS sample.     
 
Chronicity of Depression 
 Adolescents’ treatment expectancies for COMB, CBT, and medication were not 
correlated with chronicity of depression prior to treatment randomization. For teens 
assigned to COMB or CBT, total C-RAEI scores were correlated with chronicity of 
depression (see Table 6).  
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Table 6. Correlations among Treatment Expectancy and Symptom Measures 
________________________________________________________________________________________________________ 
___________________________________2.              3.              4.              5.              6.               7._ 8. 9.____   10._____ 
1. Treatment expectancy                          .461**       .537**     -.106          .072  -.124*           .027 .009 .012      .063 
    for COMB                   
 
2. Treatment expectancy                                           .117*        -.109          .095        .058              .178**   .105*    .029      .014                                 
    for CBT 
 
3. Treatment expectancy                                         -.088           .073        -.033            .064       .065      .042      .086 
    for medication only 
 
4. C-RAEI***                                                                                    -.009       -.056             -.003      -.001    .147*    .083 
 
5. CDRS-R          .404**          .229**   .334**   .116*    .137** 
 
6. RADS                    .589**   .598**  -.002     .039 
 
7. BHS                       .465** -.043      -.038 
    
8. SIQ                 .051       .083 
 
9. Duration of CDE****                   .107* 
 
10. Number of comorbid 
disorders_________________________________________________________________________________________________ 
*p<.05, **p<.01 
***C-RAEI scores were not found to be correlated with treatment expectancy for COMB, CBT, and medication only, although 
they were found to be correlated with assigned TE in a follow-up analysis (R=-.186, p=.013). 
****Duration of current depressive episode (in weeks) 
  
51 
 
Figure 1. Mean Expectancy Scores for CBT based on Depression Severity Groupings 
  
Hopelessness and Suicidality 
Adolescents’ expectancy scores for CBT were found to be correlated with their 
self-rated hopelessness (p<.001) and suicidality (p=.036) scores (see Table 6); as teens’ 
hopelessness and suicidality increased, their expectations for improvement with CBT (but 
not for COMB or medication only) decreased.  
 
Comorbidity 
Previously, the presence of a comorbid anxiety disorder and a higher number of 
comorbid disorders were found to predict poorer response to treatment in TADS (Curry 
et al., 2006). While the latter was not found to correlate with treatment expectancy in this 
study sample, differences in treatment expectancy scores for medication were found 
between adolescents with and without a comorbid anxiety disorder diagnosis. 
Adolescents with a comorbid anxiety disorder (n=112) had lower treatment expectancies 
for medication only compared to teens without a comorbid anxiety disorder (n=289), 
  
52 
 
t(399)=-2.15, p=.032 (see Figure 2). Participants with and without a comorbid anxiety 
disorder did not differ in their expectations for COMB [t(176.68)=-1.35, p=.177] or CBT 
[t(397)=-1.71, p=.089]. Additionally, C-RAEI scores did not differ between participants 
based on the presence of a co-occurring anxiety disorder [t(191)=.33, p=.74].  
 
Figure 2. Treatment Expectancies for Adolescents with and without a Comorbid Anxiety 
Disorder Diagnosis 
 
 
Note: Lower expectancy scores indicate higher treatment expectancies. 
 
Hypothesis 1.4 
 There were no differences found in treatment expectations for COMB 
F(12,386)=.84, p=.61], CBT [F(12,387)=1.22, p=.264], or medication only 
F(12,389)=1.49, p=.12] between the thirteen sites. However, after randomization to 
treatment, there were differences found between treatment sites in terms of participants’ 
expectations for their assigned treatments [F(12,390)=1.75, p=.054, ηp2=.051] with 
Tukey’s HSD revealing significant differences between sites 1 and 3 (p=.049) and 
between sites and 1 and 11 (p=.014); adolescents at site 1 had lower treatment 
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expectancies for their assigned treatment conditions compared to adolescents at site 3 and 
11 (see Table 7). A one-way between subjects ANOVA did not find site differences 
based on the C-RAEI [F(12,180)=.81, p=.63]. Table 8 also illustrates the differences in 
enrolled subjects between the thirteen sites. 
 
Table 7. Adolescents’ Assigned TEs by Site 
 
Site         n M(SD)_  
1. New York University Medical Center    19 2.68(1.11) 
2. Wayne State University Health Center    10 2.27(.72) 
3. Carolinas Health Care System     19 2.30(.67) 
4. University of Texas Southwestern Medical Center at Dallas 34 2.36(.71) 
5. University of Nebraska Medical Center    81 2.48(.66) 
6. University of Chicago Medical School    8 2.38(.74) 
7. University of Oregon Psychology Department   61 2.43(.69) 
8. John Hopkins University Medical Center    33 2.23(.77) 
9. The Children’s Hospital of Philadelphia    17 2.37(.58) 
10. New York State Psychiatric Institute     32 2.49(1.18) 
11. Children’s Hospital Medical Center (Cincinnati, OH)  39 2.15(.58) 
12. Northwestern University Medical School   18 2.52(.78) 
13. Case Western Reserve University School of Medicine  27 2.43(.67) 
 
Hypothesis 2.1 
Assigned TE (CDRS-R, RADS, and CGI-I) 
 Random coefficients regression analyses were conducted to test the hypothesis 
that treatment expectancy predicts but does not moderate treatment outcome. First, the 
results of the original TADS findings (TADS TEAM, 2004) were replicated with the 
current study sample. Similar to the original findings, there was a main effect for time 
[F(1,195.37)=745.29, p<.001], a treatment by time interaction [F(3,796.36)=7.52, 
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p<.001], and a main effect for site [F(12,388.76)=2.95, p=.001].1 Pairwise comparisons 
on adjusted week 12 means indicated that COMB outperformed CBT (p=.014) and PBO 
(p=.001), while FLX outperformed CBT (p<.001). 
Next, RRM was used to replicate Curry and colleagues’ 2006 finding that 
treatment expectancy predicted but did not moderate treatment outcome according to the 
CDRS-R. In contrast to the previous analysis using GLM, both 2- and 3-way interaction 
terms with treatment expectancy were included in the model and were subsequently 
removed from the model when they were found to be non-significant. The remaining 
model included significant effects of time [F(1,212.38)=775.87, p<.001], treatment by 
time [F(3,805.27)=7.65, p<.001], treatment expectancy [F(5,1032.8)=3.58, p=.003], and 
site [F(12,398.35)=3.00, p<.001]. Pairwise comparisons based on adjusted week 12 
means indicated that adolescents who expected their depression problems to become 
“much improved” with their assigned treatments had a better outcome than adolescents 
who expected their depression problems to become “minimally improved” with their 
assigned treatments (p=.011). The means and standard deviations of teens’ CDRS-R 
scores are listed in Table 9 according to teens’ assigned TEs and depression severity 
levels.  
Figure 3 provides a graphic illustration of Table 8 for adolescents who expected 
their depression problems to be “very much improved,” “much improved,” “minimally 
improved,” and “not changed.” Teens who expected their depression problems to worsen 
with treatment are not included in the graph due to their relatively small numbers. 
                                                 
1
 In the original analysis (TADS TEAM, 2004), site was categorized as a random effect. Because the 13 
sites in TADS were not randomly selected, the TADS TEAM decided to categorize site as a fixed effect in 
subsequent publications. The decision to include site as a fixed effect resulted in a significant finding for 
site, which was not found in the original analysis. 
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Table 8. CDRS-R Scores over Time Based on Severity of Depression and Assigned TEs 
 
         CDRS-R 
Treatment Expectancy      Severity*    n**        Week 0    Week 6    Week 12 
                     M(SD)            M(SD)    M(SD) 
1=“Very much improved”      0 36    52.22(7.91)     33.40(9.73)     30.13(9.25) 
                                     1          43           65.63(8.27)     42.53(14.07)   37.33(14.38) 
                     Total 79    59.52(10.49)   38.82(13.08)   34.00(12.66) 
2=“Much improved”  0           69          52.51(6.16)     38.90(9.56)     35.26(12.27) 
    1           84          64.36(9.15)     43.13(13.68)   37.11(12.92) 
          Total 153         59.01(9.89)     41.31(12.22)   36.31(12.62) 
3=“Minimally improved”       0           51          53.27(6.11)     40.44(11.37)   39.09(11.14) 
    1           78          66.65(9.85)     48.10(11.64)   41.67(14.13) 
          Total         129        61.36(10.78)   45.04(12.12)   40.78(13.06) 
4=“Not changed”  0           14          54.86(8.07)     36.44(8.43)     34.73(4.05) 
    1           21    65.14(10.17)   44.05(11.21)   48.63(17.06) 
           Total         35    61.03(10.57)   40.03(11.71)   43.53(17.01) 
5=“Minimally worse”         1(Total)    3           66.33(3.22)      42.67(2.89)     52.00(14.42)  
7=“Very much worse” 0           1            54.00               49.00               39.00          
    1           2            61.50(.71)       62.00               49.00(21.21)  
                      Total          3           59.00(4.36)      55.50(9.19)     45.67(16.07) 
Note: Adolescents who expected their depression to worsen with treatment are not 
included in the table due to their relatively small numbers. 
*0=Mild-moderate depression, 1=Marked-severe depression 
**n reflects the number of adolescents at week 0. 
 
Figure 4 provides a graphic illustration of Table 9 for adolescents who expected 
their depression problems to be “very much improved,” “much improved,” “minimally 
improved,” and “not changed.” Teens who expected their depression problems to worsen 
with treatment are not included in the graph due to their relatively small numbers. 
The same process of random regression modeling and model selection was 
conducted with the RADS replacing the CDRS-R as the outcome variable. The following 
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Figure 3. CDRS-R Scores over Time Based on Assigned TEs 
 
fixed effects were found to be significant: Treatment [F(3,751.13)=2.95, p<.001], time 
[F(1,663.59), p=.032], treatment by time [F(3,736.02)=3.83, p=.01], site 
[F(3,751.13)=2.95, p<.001], and assigned TE by time [F(5,715.67)=2.33, p=.04]. The 
effect of treatment expectancy on outcome was not significant by itself 
[F(5,761.25)=1.31, p=.26]. Paired contrasts on adjusted means at week 12 showed 
differences in outcome between adolescents who expected their depression problems to 
be “very much improved” and adolescents who expected their depression problems to be 
“minimally improved” with treatment (p=.053); see Table 9 and Figure 4. As in Figure 3, 
adolescents who expected their depression problems to worsen with treatment were not 
included in the graph. 
In the original TADS sample (n=439), the following percentages of adolescents 
were categorized as responders to treatment (“very much improved” or “much 
improved”) according to the clinician-rated CGI-I: COMB (71%), FLX (60.6%), CBT, 
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pairwise contrasts revealed the following relationships based on treatment response: 
COMB=FLX>CBT=PBO. 
 
Table 9. RADS Scores over Time Based on Severity of Depression and Assigned TEs 
         RADS 
Treatment Expectancy      Severity*    n**        Week 0    Week 6    Week 12 
                     M(SD)            M(SD)    M(SD) 
1=“Very much improved”      0 36 75.06(12.20)    56.37(14.24)    49.87(12.03) 
                                     1          43        81.47(15.25)    66.87(18.23)    59.38(17.17) 
                     Total 79 78.54(14.23)    62.24(17.29)    55.17(15.75) 
2=“Much improved”  0           68       75.24(10.49)    62.80(12.58)    57.93(13.40) 
    1           83       83.53(13.33)    67.91(16.67)    63.41(16.02) 
          Total 151      79.79(12.78)    65.76(15.25)    60.98(15.12) 
3=“Minimally improved”       0           51       74.57(15.69)    66.44(15.79)    64.51(15.68) 
    1           77       82.51(13.97)    71.44(16.66)    67.70(18.61) 
          Total         128      79.34(15.13)    69.47(16.43)   66.47(17.54)    
4=“Not changed”  0           14        67.57(16.76)   61.11(18.00)    60.27(14.60)  
    1           21        84.43(14.40)   71.25(16.14)    72.55(20.24) 
           Total         35 77.69(17.31)    68.10(17.09)    68.19(19.14) 
5=“Minimally worse”         1(Total)      3       86.00(9.17)      72.00(16.82)   75.33(8.74)  
7=“Very much worse” 0             1        49.00               64.00               51.00 
    1             2        79.00(39.60)   114.00             99.00           
                      Total            3        69.00(32.92)   89.00(35.36)   75.00(33.94) 
Note: Adolescents who expected their depression to worsen with treatment are not 
included in the table due to their relatively small numbers. 
*0=Mild-moderate depression, 1=Marked-severe depression 
**n reflects the number of adolescents at week 0. 
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Figure 4. RADS Scores over Time Based on Assigned TEs 
 
 
Responder rates in the current study sample were similar to the original sample 
for COMB (74.3%), FLX (61.6%), CBT (42.2%), and PBO (36.6%). Likewise, logistic 
regression revealed a significant treatment effect (Wald χ2=37.3, p<.001) with 
COMB=FLX>CBT=PBO (site was not significant). When assigned TE was added to the 
model, both treatment (Wald χ2=34.1, p=.001) and assigned TE contributed to the 
regression model (Wald χ2=12.2, p=.03). Adolescents who expected their depression to 
become “very much improved” were more likely to respond to treatment than adolescents 
who expected minimal improvement (p=.002) or no improvement (p=.004) with 
treatment. Adolescents who expected their depression problems to be “much improved” 
were also more likely to respond to treatment compared to adolescents who expected 
minimal (p=.004) to no improvement (p=.014) with treatment. Figure 5 illustrates the 
percentage of responders to treatment for each of these four groups. 
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Figure 5. Percentage of Responders to Treatment Based on Assigned TEs 
 
C-RAEI (CDRS-R, RADS, and CGI-I) 
 Attempts were made to fit a random coefficients regression model to the data 
using C-RAEI in place of treatment expectancy as a predictor variable for both the 
CDRS-R and the RADS as outcome measures. However, the models failed to converge. 
Subsequent analyses were performed using GLM for repeated measures. Similar results 
were obtained to the RRM analyses in terms of treatment, site, and treatment by time 
interactions. However, total C-RAEI scores did not predict CDRS-R or RADS scores 
over time. Additionally, total C-RAEI scores did not predict responder status, as 
measured CGI-I, using logistic regression.   
 
Hypothesis 3.1 
 The hypothesis that assigned TE would predict completer status (yes/no) was not 
supported using logistic regression (Wald χ2=3.02, p=.70). Treatment and site also did 
not predict completer status, or alternatively, whether or not participants dropped out of 
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TADS. The C-RAEI also failed to predict completer status (Wald χ2=.09, p=.77) for 
adolescents assigned to COMB or CBT. 
 
Hypothesis 4.1 
Assigned TE (CDRS-R, RADS, and CGI-I) 
 The hypothesis that severity of depression would moderate the relationship 
between treatment expectancy and treatment outcome was supported by the data. An 
RRM including treatment, time, site, severity, treatment expectancy, as well as their 2- 
and 3-way interactions, revealed significant effects of time [F(1, 681.86)=107.37, 
p<.001], treatment by time [F(3,739.68)=7.97, p<.001], site [F(12,460.21)=2.84, 
p=.001], severity [F(1,798.00, p<.001], and a 3-way interaction between treatment 
expectancy, severity, and time [F(10,744.89)=4.08, p<.001]; see Table 8. Figures 6 and 7 
illustrate rates of improvement based on treatment expectancy levels for adolescents with 
mild to moderate depression and marked-severe depression, respectively. Rates of 
treatment response for adolescents with mild to moderate depression appear more 
sensitive to their assigned TEs when compared to adolescents with marked to severe 
depression.   
Paired contrasts indicated that adolescents with mild to moderate depression who 
believed their depression problems would be “very much improved” with their assigned 
treatments had lower CDRS-R scores at week 12 than adolescents who believed their  
depression problems would be “minimally improved” with treatment (p=.003). For 
adolescents with marked to severe depression, adolescents who believed their depression 
would be “very much improved” (p=.023) and “much improved” (p=.009) with 
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treatment had lower CDRS-R scores at week 12 than adolescents who did not expect their 
depression to improve (“not changed”).   
 
Figure 6. Mild-Moderately Depressed Adolescents’ Improvement over Time by Assigned 
TEs 
 
Figure 7. Moderately-Severely Depressed Adolescents’ Improvement over Time by 
Assigned TEs 
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Similar results were obtained with the RADS as the outcome variable, in which 
the following effects were found by running a random regression model: Time 
[F(1,656.25)=12.48, p<.001], treatment by time [F(3,721.48)=4.14, p=.006], site 
[F(12,508.82)=5.16, p<.001], severity of depression [F(1,761.83)=20.59, p<.001], and a 
3-way interaction between assigned TE, severity of depression, and time 
[F(9,699.31)=1.98, p=.039]; see Table 9. Adolescents with mild to moderate depression 
and the highest assigned TEs (“very much improved”) had lower RADS scores at week 
12 compared to adolescents who expected “much” (p=.05) and “minimal” (p<.001) 
improvement with their assigned treatments, while marked to severely depressed teens 
with the highest level of assigned TEs (“very much improved”) had lower RADS scores 
after 12 weeks of treatment compared to adolescents who did not expect any 
improvement (“not changed”) with their assigned treatments.            
A significant 3-way interaction between treatment expectancy, severity of 
depression, and time was not found using logistic regression with the CGI-I (responder 
versus non-responder) as the outcome variable, so it was subsequently taken out of the 
model. The reduced logistic regression model revealed the following significant predictor 
variables: Treatment (Wald χ2=43.44, p<.001), site (Wald χ2=39.36, p<.001), severity of 
depression by treatment (Wald χ2=22.22, p<.001), and severity of depression by assigned 
TE (Wald χ2=44.75, p<.001). Rates of response differed between the two severity groups 
for adolescents who expected their depression to be “very much improved” (p=.01), but 
not for teens in the other expectancy groups (see Figure 8). 
 Subsequent chi-square analyses were conducted separately on the percentage of 
responders at week 12 for the two severity groups, excluding adolescents who expected 
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Figure 8. Percentage of Responders Based on Severity of Depression and Assigned TEs 
   
their depression to worsen with treatment. For participants with mild to moderate 
depression, percentage of responders differed by treatment at rates greater than expected 
by chance χ2(3, N=170)= 19.6, p<.001. This was not the case for adolescents with 
marked to severe depression. For adolescents with mild to moderate depression levels, 
those who expected “very much” improvement with treatment were more likely to 
respond to treatment than those with expected “mild” improvement (p<.001) or no 
improvement (p=.04). Teens who expected “much” improvement also were more likely 
to respond to treatment than adolescents who expected “mild” improvement (p=.003). 
 
C-RAEI (CDRS-R, RADS, CGI-I) 
 General linear models for repeated measures were used to test the hypothesis that 
there is an interaction between severity of depression and C-RAEI total scores. Time 
[F(2,270.00)=11.38, p<.001], treatment by time [F(4,270.0)=11.01, p<.001] and site by 
time [F(24.0,270.0)=1.88, p=.009] emerged as predictors for treatment outcome with 
Huynh-Feldt correction, as measured by the CDRS-R. However, total C-RAEI scores did 
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not emerge as a predictor in the model, alone or in combination with time, treatment, or 
severity of depression.  
 The same analyses were conducted with the RADS in place of the CDRS-R with 
slightly different findings. In this model, the following terms were identified as 
significant: Treatment [F(1,125)=5.78, p=.004], site [F(12,125)=1.87, p=.04],  treatment 
by time [F(4,250)=11.78, p<.001], and a 3-way interaction between severity of 
depression, C-RAIE total scores, and time [F(2,250)=3.26, p=.04]. Subsequent 
correlations indicated that C-RAIE total scores predicted week 12 RADS scores for teens 
with marked to severe depression (R=-.25, p=.006) but not for teens with mild to 
moderate depression (R=-.146, p=.133). Therefore, adolescents who accepted the 
treatment rationale for CBT and had higher treatment expectancies, as measured by the 
C-RAIE, were more likely to improve with treatment if they suffered from marked to 
severe depression.  
 In contrast, logistic regression identified a significant effect of treatment (Wald 
χ
2
=14.52, p<.001) in predicting responders versus non-responders to treatment according 
to the CGI-I, but did not identify any other significant main effects (site, time, C-RAIE 
totals) or interactions for teens assigned to COMB or CBT.  
 
Hypothesis 5.1 
 Finally, the hypothesis that COMB would continue to outperform the other three 
treatment conditions after controlling for treatment expectancy was supported by the data. 
As reported in the results section (see above) of hypothesis 2.1, treatment and/or 
treatment by time were significant predictors of treatment response when treatment 
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expectancy was included in the model, regardless of whether outcome was measured by 
the CDRS-R, the RADS, or the CGI-I. 
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CHAPTER IV 
DISCUSSION 
 
Summary of Findings 
 
Adolescent Characteristics and Treatment Expectancy in TADS  
 
As hypothesized, TADS adolescents endorsed higher treatment expectations for 
COMB compared to CBT and medication only. The majority of adolescents (76.3%) 
believed that their depression problems would become “very much improved” or “much 
improved” with COMB, most of whom (43.6%) posited the former belief. Approximately 
half of the participants reported that they expected their depression problems to be at least 
“much improved” from a course of treatment with CBT or medication only. Expectations 
for improvement did not differ between these two treatments. This information is 
noteworthy given that very little is known about treatment expectancy in children and 
adolescents.  
A related concept of comparison is treatment preference. Investigators recently 
surveyed students in a rural, Nova Scotia high school about their preferences for 
depression treatment if they were to become depressed. Students expressed a strong 
preference for psychotherapy over pharmacotherapy (92% of boys and 94.9% of girls) 
with 48% of the sample reporting that they would refuse antidepressant treatment due to 
its potential side effects (Bradley, McGrath, Brannen, & Bagnell, 2010). Previously, 
Jaycox, Asarnow, Sherbourne, Rea, LaBorde, and Wells (2006) found that adolescents 
who screened positive for depression in primary care preferred counseling (50%) over 
medication (22%). Negative attitudes about depression treatment, positive attitudes about 
medication treatment, as well as current anxiety symptoms were associated with 
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preference for medication. Both of these studies suggest that adolescents tend to prefer 
psychotherapy for the treatment of depression, while TADS teens did not report higher 
expectations for one over the other. Differences between these findings and the current 
study’s findings may reflect differences between treatment preference and expectancy, 
study methods, and/or sample characteristics, and are not well understood.  
In the current study, age and race/ethnicity were not associated with treatment 
expectancy for COMB, CBT, or medication only. There was a tendency for adolescent 
females to report higher expectations for COMB compared to adolescent males, whereas 
no gender differences were found in treatment expectations for either monotherapy. 
Interestingly, adolescents with family income levels below $75,000 reported lower 
treatment expectancies for CBT (but not for COMB or medication only) than adolescents 
with family income levels at or above this cutoff. Combined with the finding that 
treatment expectancy predicts outcome, this may partially explain why income moderated 
treatment response in TADS. Curry and colleagues (2006) found that adolescents with 
family income levels at or above $75,000 responded as well to CBT as COMB and FLX, 
and were more likely to respond to CBT than PBO. In contrast, adolescents with family 
income levels below $75,000 demonstrated a similar rate of response to CBT and PBO. 
In Safren, Heimberg, and Juster’s 1997 study investigating the efficacy of group 
CBT for the treatment of social phobia, the investigators found that adults who had 
completed some postgraduate education had higher expectations for improvement with 
CBT than adults who had not completed high school, which in turn, predicted higher 
rates of treatment response. The authors speculated that level of education may be 
correlated with confidence in one’s ability to master cognitive-behavioral techniques and 
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benefit from treatment. Self-efficacy has been found to differ between adolescents based 
on their socioeconomic status (Hannah & Kahn, 1988). It is possible that adolescents 
with lower family income levels doubted their ability master CBT techniques and benefit 
from treatment. This may explain why adolescents with family income levels between 
$20,000 and $39,999 tended to have lower expectations for CBT and COMB (but not 
medication without CBT) than their wealthier peers; in comparison to CBT, treatment 
with medication is likely perceived as requiring more passive participation. 
Severity of depression, hopelessness, and suicidality were similarly found to be 
negatively correlated with expectancy for CBT, but not for COMB or medication only. 
Therefore, it was not the case that these markers of illness severity predicted lower 
expectations for treatment in general. More severely ill adolescents in TADS may have 
believed that medication (either alone or in combination with CBT) was necessary in 
order to alleviate their depressive symptoms. The underlying assumption behind this 
belief is that medication is a stronger treatment for depression than CBT. Alternatively, 
adolescents with greater severities of illness may have conceptualized their depression as 
more biological in nature, thus requiring a more “biological” treatment. The fact that 
severity of depression was positively associated with higher treatment expectations for 
COMB suggests that despite lower expectations for CBT, adolescents with more severe 
depression perceived additional benefit with CBT in combination with medication. 
The only factor found to be associated with treatment expectancy for medication 
without CBT was the presence of a comorbid anxiety disorder. Adolescents with a co-
occurring anxiety disorder diagnosis had lower expectations for improvement with 
medication than their peers. This is not entirely explained by anxiety over medication 
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side effects, since there were no differences in expectations for COMB based on 
comorbidity. Perhaps, adolescents prone to anxiety had more concerns about medication 
without the additional monitoring of a therapist. Taken together, these results suggest that 
treatment expectancy varies by treatment and adolescent characteristics. More research is 
needed in order to understand how an adolescent’s knowledge of treatment, perceived 
self-efficacy, and perceived treatment fit (e.g. whether or not the treatment is seen as 
addressing one’s problems) contribute to treatment expectancy. 
 
Treatment Expectancy Predicts Treatment Response 
Curry and colleagues (2006) initially reported that treatment expectancy predicts 
but does not moderate treatment outcome. This appears to be a robust finding, appearing 
in generalized linear, randomized coefficient, and logistic regression models with both 
clinician-rated and adolescent-rated measures of treatment response. Regardless of 
treatment, adolescents’ expectations for improvement with their assigned treatments 
impacted their treatment response. Perhaps most noticeably, the percentage of responders 
to treatment (based on the CGI-I) decreased in a linear fashion as participants’ treatment 
expectations went down (see Figure 5). 
Lewin, Peris, Bergman, McCracken, and Piacentini (in press) also demonstrated 
that treatment expectancy was positively associated with treatment response in a study of 
exposure-based treatment for childhood OCD. The investigators found that children’s 
baseline depressive symptoms, but not their severity of OCD symptoms, were associated 
with treatment expectancy. In addition to treatment response, expectancy predicted 
homework compliance and study completion. Homework was not examined in the 
current study, and is currently being examined in a separate TADS paper (Simons et al., 
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in progress), while treatment expectancy did not predict study completion in TADS. 
Combined with Lewin et al.’s results, TADS provides initial evidence that treatment 
expectancy is an important consideration in the treatment of mood and anxiety disorders 
in children and adolescence. 
For the most part, the finding that treatment expectancy predicts treatment 
outcome in TADS is consistent with the adult literature. As mentioned previously, 
Arnkoff, Glass, and Shapiro (2002) found support for a positive relationship between 
expectancy and outcome in 12 studies, mixed support in seven studies, and null findings 
in five studies. These 24 studies are difficult to compare to each other due to their 
different populations, treatments under investigation, measurements of expectancy, 
timing of assessments, and statistical procedures. For example, of the studies reviewed in 
my introduction, only one study utilized hierarchical linear modeling (Price, Anderson, & 
Heinrich, 2008) similar to the statistical methods employed in the current study. The 
researchers found that treatment expectancy predicted treatment gains during therapy but 
not during follow-up in a study of virtual reality exposure and in vivo exposure for the 
treatment of flying phobia.  
Notably, the investigators found poor internal consistency for their initial measure 
of expectancy, which included the following three items: 1) confidence that therapy 
would reduce fear of flying-related symptoms, 2) confidence that therapy would reduce 
other fears, and 3) how logical treatment seemed. They subsequently decided to use the 
first item alone as their measure of treatment expectancy given its high face validity. As 
Lorber, Mazzoni, and Kirsch (2007) advocate, response expectancy is specific to one’s 
expectations. It is unclear why participants would expect treatment for flying phobia to 
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reduce other fears (item 2), while item 3 appears to target acceptance of treatment 
rationale rather than treatment expectancy.  
Borkovec and Nau’s 1972 credibility/expectancy questionnaire, which consists of 
four questions, includes one question that measures treatment credibility (“At this point, 
how logical does this therapy seem to you at this point?”). This measure has been shown 
to predict treatment response (e.g. Chambless, Chan, & Glass, 1997). Almost thirty years 
after its creation, Devilly and Borkovec (2000) investigated the psychometric properties 
of this measure, and derived two predicted factors from the measure, a cognitively based 
credibility factor and a more affectively based measure of expectancy. The measure was 
found to have high internal consistency within each factor, and test-retest reliability 
across different populations. The expectancy, but not the credibility factor, was found to 
be associated with outcome. The investigators hypothesized that credibility scales are 
cognitively related, while expectancy scales are more affective-based. It is possible that 
the Treatment Expectancy for Adolescents (TEA) and the CBT Rationale Acceptance and 
Improvement Expectancy (C-RAIE) measures, both specifically designed for TADS, 
tapped into different constructs, which subsequently led to different findings. 
 
C-RAIE Scores Do Not Predict Treatment Outcome 
 
While the single-item measure of treatment expectancy (derived from the TEA) 
predicted treatment response in TADS, total C-RAIE scores for adolescents assigned to 
CBT or COMB did not. The C-RAIE consists of six items, three of which were designed 
to measure acceptance of treatment rationale. The measure was found to have high 
internal consistency in the current study, which is indicative of one latent variable. 
Therefore, it is unlikely that non-significant findings for the C-RAIE can be attributed 
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solely to its inclusion of items designed to measure acceptance of treatment rationale. 
Moreover, acceptance of treatment rationale has been found to predict treatment outcome 
in studies of CBT for depression (Addis & Jacobson, 2000; Fennell & Teasdale, 1987). 
Differences found between the TEA and the C-RAIE, rather, can be attributed to 
discrepancies in the timing of the two assessments and their statistical power; while the 
TEA was administered to the entire study sample prior to adolescents finding out their 
randomized treatment assignments, the C-RAIE was only administered to adolescents 
assigned to CBT or COMB (half the sample) during their second session of CBT.  
Adolescents filled out the TEA with very little treatment information (typically no 
more than a couple of sentences for each of the treatment arms) provided by study staff 
(e.g. “CBT is a type of psychotherapy that has been shown to be effective for the 
treatment of depression.”). Presumably, adolescents varied greatly in terms of their 
knowledge of CBT, antidepressant medication, and the combination of the two treatments 
when they entered TADS. The C-RAIE, in comparison, was administered after 
adolescents were made aware of their treatment assignments and had experienced some 
exposure to CBT. Specifically, session 1 included the following goals: 1) to begin to 
establish a collaborative therapeutic relationship, 2) to review briefly the major findings 
from assessment and relate these to the model of depression, 3) to explain rationale for 
CBT; rationale for family involvement; and how this treatment can help, 4) to elicit 
adolescent’s and parents’ initial goals for treatment, and 5) to review no-suicide contract 
and answer questions about treatment (Curry et al., 2000).  
TADS therapists provided an extensive amount of information to adolescents and 
their parents at session 1, including written handouts. Furthermore, in the TADS’ CBT 
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treatment manual, therapists were encouraged to convey hopefulness to adolescents 
during this session, and were instructed to describe depression as a learned pattern that is 
capable of being changed, thus instilling further hope for improvement. Therapists were 
specifically instructed to point out to adolescents receiving COMB that medication can 
also change this pattern [“It (medication) can especially help to get the changes started as 
adolescents learn new skills. Then, the new skills can take over and the medication will 
not be necessary.”]. Adolescents were reminded of the treatment rationale for CBT in 
session 2, prior to filling out the C-RAIE.  
How might this account for the finding that the C-RAIE did not predict treatment 
response for adolescents assigned to CBT, either alone or in combination with FLX?  
One hypothesis is that treatment expectancy is more important prior to treatment 
initiation. Research suggests that treatment gains early in therapy predict treatment 
outcome, especially when these gains are “sudden” (occurring between two sessions; 
Tang & Deurbeis, 1999). For example, Kelly, Robert, and Ciesla (2005) found that 
sudden gains occurring in the first third of CBT for depression treatment led to larger 
symptom reductions over time and treatment response. In a more nuanced study, Busch, 
Kanter, Landes, and Kohlenberg (2006) compared sudden gains that occurred after initial 
assessment, after one session of cognitive therapy, and single-session gains that occurred 
after at least two sessions of therapy. First-session gains and gains that occurred in the 
first half of treatment predicted positive outcome in adults with depression.  
Since early sudden gains often occur before the “specific” interventions of 
treatments are administered (e.g. thought records in CBT), some researchers have 
speculated that placebo/expectancy and other common factors of treatment account for 
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early sudden gains (Haas, Hill, Lambert, & Morrell, 2002). However, Tang and DeRubeis 
initially reported that CBT clients demonstrated cognitive changes (a primary target of 
CBT) in the session directly prior to their sudden gains, which they attributed to clients’ 
symptom reduction.  
Based on the current study’s findings, it is hypothesized that treatment expectancy 
may be more predictive of early response to treatment, while other factors may account 
for improvement later on in treatment. Future research is necessary in order to draw any 
firm conclusions about the importance of treatment expectancy in different stages of 
treatment. Since the TEA was not re-administered in conjunction with the C-RAIE after 
starting CBT, it is unclear whether or not the information provided in session 1 of CBT 
increased or decreased adolescents’ expectations for improvement with CBT. Some teens 
may have been disappointed to learn that CBT requires significant effort (e.g. homework) 
with an emphasis on learning (much like school) if they had mostly wanted and expected 
psychotherapy to consist of someone compassionate to talk (i.e. supportive therapy), 
while other teens’ expectations may have improved after learning about CBT’s focus on 
the present and its inclusion of problem-solving. 
 
Severity of Depression Moderates the Effect of Treatment Expectancy on Outcome 
 The hypothesis that severity moderates the relationship between treatment 
expectancy and outcome was supported by the TADS data. Two- or three-way 
interactions between adolescents’ expectation for improvement with their assigned 
treatment condition (i.e. assigned TE), severity of depression (mild-moderate versus 
marked-severe depression), and time (in the case of three-way interactions) were found to 
be significant for each of the primary outcome measures in TADS using random 
  
75 
 
coefficients and logistic regression. If it is true that mild to moderately depressed 
adolescents are more sensitive to the effects of expectancy, we would expect to see 
increasingly smaller rates of recovery as treatment expectancy decreased (“very much 
improved”>“much improved”>“minimally improved”>“not changed”), which is indeed 
evidence in Figure 6. The same pattern was not evident for adolescents with marked to 
severe depression, although there were differences in outcome between the groups 
farthest apart from each other (“very much improved”>“not changed”), which implies 
that treatment expectancy still matters for these teens. 
 These results are consistent with research suggesting that the placebo response is 
less likely to occur in more severe forms of psychopathology (Shapiro & Shapiro, 1997); 
it is also consistent with research indicating that antidepressants are especially likely to 
outperform placebo for individuals with more severe forms of depression (Khan et al., 
2002; Wilcox et al., 1992; Fairchild et al., 1986), where expectancy effects are less 
powerful, thus requiring the more “active” ingredients of medication. To my knowledge, 
this is the first study to examine severity of depression as a moderator of treatment 
expectancy on outcome; although preliminary, it is notable that for all of the three 
primary measures of expectancy, significant interactions were found between severity of 
depression and adolescents’ expectations for improvement with their assigned treatment 
conditions.   
 When total C-RAIE scores replaced assigned TEs in the random coefficients and 
the logistic regression analyses, a significant interaction between total C-RAIE scores and 
severity of depression was found for the TADS’ self-rated outcome measure (i.e. RADS), 
but not for the two primary clinician-rated measures. The C-RAIE was associated with 
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treatment outcome for marked to severely depressed teens, but not for mild to moderately 
depressed teens. This finding is perplexing and raises further questions about the methods 
and timing of assessment of treatment expectancy. What is seems to suggest, however, is 
that it may be especially important for marked to severely depressed adolescents to “buy-
in” to CBT after their initial session, perhaps in order to increase treatment engagement. 
There may also be a difference between severely depressed adolescents who, after 
hearing about the rationale for CBT, accept the rationale and have higher expectations for 
improvement than adolescents who are exposed to the same rationale and remain 
skeptical about CBT.  
A study conducted by Fennell and Teasdale (1987) is of particular relevance to 
this finding. The investigators examined clients’ acceptance of treatment rationale in a 
treatment outcome study for depression with CBT. After reading Beck and Greenberg’s 
1974 Coping with Depression booklet (designed to provide clients with an introduction to 
CBT), clients were asked to share their reactions to the booklet. Acceptance of treatment 
rationale, as coded by independent evaluators based on clients’ recorded reactions, 
predicted client outcomes at three and six months. Interestingly, the investigators also 
found that higher levels of “depression about depression” early in treatment were 
associated with both acceptance of treatment rationale and subsequent response to CBT.  
“Depression about depression” refers to beliefs consistent with the idea that 
depression is untreatable, one’s own fault (e.g. based on a character flaw), and not 
capable of being understood. Although it is not often identified in the more recent studies 
of depression, “depression about depression” is an important concept given its correlation 
with depression severity (Fennell & Cambell, 1984). Fennell and Teasdale speculated 
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that adolescents depressed about their depression may have received considerable benefit 
(e.g. symptom reduction and increased feelings of hope) from increased insight into their 
depression after reading Coping with Depression and learning more about the CBT 
model. The same reasoning can be applied to severely depressed TADS participants. It is 
possible that severely depressed TADS adolescents who endorsed acceptance of 
treatment rationale and higher expectations for improvement with CBT after learning 
about the CBT model may have suffered from “depression about depression” prior to 
treatment initiation. For these adolescents, we might expect a clear and convincing 
treatment rationale to be particularly important, both in terms of raising treatment 
expectations and increasing treatment engagement.  
 
Treatment Expectancy and Treatment Effects Contribute Separately to Outcome 
 
 The final aim of the current study was to investigate whether or not treatment 
expectancy accounts for COMB’s superior performance in the acute phase of TADS. As 
previously discussed, the “uneven blind” in TADS has been criticized as a flawed design 
of the study (Jureidini, Tonkin, & Mansfield, 2004). The uneven blinding in TADS refers 
to the fact that adolescents assigned to COMB and CBT were cognizant of their treatment 
assignments, while adolescents assigned to one of the “pills only” conditions were 
unaware of whether they were receiving FLX or PBO.  Thus, treatment expectancy 
effects were presumably controlled for in the “pills only” conditions, but not for 
adolescents receiving CBT (alone or in combination with medication). Given that 
independent evaluators and adolescents were able to guess teens’ assigned treatment 
conditions at rates greater than expected by chance alone, it is likely that expectancy 
influenced both clinician- and self-rated measures of outcome.  
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   The current study found that both treatment expectancy and treatment (either 
alone or in combination with time) predicted treatment outcome for the study’s three 
primary outcome measures. It seems that treatment differences cannot be attributed to 
treatment expectancy alone. This finding is consistent with Lambert’s four-factor model, 
which attributes similar, separate, and modest (15%) effects of hope/expectancy and 
specific models/techniques. However, it is important to note that these effects are not 
easily divorced. For example, some treatments might simply make more sense than other 
treatments, and perhaps are more congruent with a person’s culture. In this case, does 
treatment expectancy function as a common or a specific factor? Similarly, certain 
treatment methods (e.g. CBT’s emphasis on “collaborative empiricism”) may engender a 
stronger treatment alliance, which in turn, may impact treatment outcome. In other words, 
the process of change likely involves a combination of common and specific factors that 
are highly interrelated and dependent on each other.  
 
Limitations and Future Directions 
There are several limitations in the current study that can be used to guide future 
research. First, although treatment expectancy was not shown to be associated with 
participants’ ethnicity/race, the TADS sample was predominantly Caucasian Americans 
and the findings of this study may not generalize to other populations. More efforts 
should be made in the future to overcome barriers that may prevent minority adolescent 
populations from participating in treatment outcome research, such as TADS. 
 Second, while 100% of teens assigned to COMB or CBT knew their assigned 
treatment conditions, a significantly smaller percentage of teens assigned to FLX or PBO 
could identify their assigned treatment conditions. At week 12, 63.9% of teens assigned 
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to FLX and 64.4% of teens assigned to PBO correctly guessed their assigned treatment 
condition. Therefore, it is likely that treatment expectancy impacted treatment outcome to 
a greater extant in COMB and CBT compared to FLX and PBO. While it is difficult to 
pinpoint the effects of treatment expectancy in blinded clinical research trials, it is 
certainly more difficult in studies with uneven blinding procedures. Future research 
studies in this area should include multiple measurements of expectancy over time 
without the use of blinding procedures, or alternatively, might include the use of blinding 
as a design feature to manipulate expectancy levels.  
Third, treatment expectations for PBO were not assessed (or, alternatively, 
adolescents’ expectations for improvement over time without treatment). Therefore, 
adolescents’ expectations for improvement with medication only were used as their 
assigned TEs for the purposes of this study. It is unclear how much of an adolescent’s 
expectations for improvement with a certain treatment could be accounted for by their 
overall expectation for improvement in general. For example, teenagers who believe their 
depression problems will be “much improved” over time without treatment, who then 
indicate that they expect to be “very much improved” with COMB treatment, perhaps 
only expect minimal improvement with COMB in addition to the effects of time. It would 
be helpful for future research studies to include a more nuanced approach to 
conceptualizing and measuring expectancy in its various forms. This would also help to 
clarify the “active” ingredients (e.g. self-efficacy, acceptance of treatment rationale, etc.) 
in different definitions of expectancy (e.g. overall versus treatment expectancy). 
Fourth, although adolescents were asked about their expectations for 
improvement with COMB, CBT, and medication only, independent evaluators, CBT 
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therapists, and pharmacotherapists were not asked to rate their expectations for the TADS 
treatments. This implies that adolescents’ expectations are more important than the 
investigators’ or the treatment providers’ expectations, which has not been demonstrated. 
In fact, it has been estimated that the correlation between researchers’ therapeutic 
allegiance and treatment outcome may be as high as .85 (Luborsky et al., 1999), and 
accounts for treatment outcome more than any other factor that has been investigated so 
far (common or specific; Wampold, 2001). By assessing investigators’ treatment 
expectancies, it may be possible to determine the extent of rater bias in randomized, 
clinical research trials.  
Fifth, the measures of expectancy in TADS were designed for the study. 
Therefore, very little is known about the psychometric properties of the measures, which 
complicates the comparison of these results to the results of other similar studies. 
Moreover, although the TEA measure appears to have face validity, it is not entirely clear 
if the measure is actually measuring treatment expectancy, or if it is a measure of a 
related or alternative construct (e.g. agreeableness). More research is needed in order to 
validate these measures and clarify the construct of treatment expectancy. Also of interest 
is the test-retest reliability of the TEA and the C-RAIE. Is treatment expectancy (and its 
related constructs) stable within an individual, or is it variable over time? Also, how 
easily is treatment expectancy manipulated? What are the best ways of increasing 
treatment expectancy? If expectancy has an affective component as Devilly and 
Borkoved (2000) suggest, how can clinicians improve the treatment expectations of their 
clients on an emotional level, especially for adolescents who may be skeptical about 
treatment? 
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Other areas for future research include the following: 1) identifying treatment 
expectancy’s mechanisms of change (e.g. through increased treatment engagement), 2) 
utilizing treatment matching strategies based on participants’ expectancies/preferences in 
order to improve outcome, 3) manipulating expectancy in randomized clinical research 
trials (assigning high versus low expectancy treatment conditions within participants’ 
treatment assignments), and 4) investigating the long-term impact of treatment 
expectancy. Basoglu, Marks, Kilic, Brewin, and Swinson (1994), for example, found that 
higher treatment expectations for pharmacotherapy were found to be associated with 
greater attributions for improvement to drug treatment in treatment responders. Greater 
attribution of improvement to medications predicted more severe withdrawal effects and 
a relapse of symptoms during follow-up, although treatment expectancy alone did not. 
This study suggests that treatment expectancy indeed matters after treatment is 
completed. One question of interest is whether assigned TE or total C-RAIE scores 
predict outcome in the later stages of TADS.  
Finally, it is important to consider the context in which treatment expectancy 
develops, changes, and is maintained. How might trauma, for example, affect 
adolescents’ expectations for particular treatments? For adolescents attempting to cope 
with chaotic living situations, it may be necessary for mental health providers to directly 
address these situations in order to increase adolescents’ treatment expectations and 
engagement early on in treatment. Also, it is likely that adolescents will endorse higher 
expectations for treatments that appear to address their problems directly. More research 
is needed in order to understand how adolescents’ environmental and historical contexts, 
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explanations for their depression problems, treatment expectations, and depressive 
symptoms influence each other over time.   
 
Conclusions 
 Despite the study limitations outlined above, very little is known about the 
treatment expectancies of children and adolescents and how it impacts treatment 
outcome. Treatment expectancy, which has been called the “ignored common factor,” 
appears to predict outcome for adolescents treated for depression, regardless of treatment. 
Adolescents had the highest expectations for improvement with COMB with the more 
severely depressed teens reporting lower expectations for CBT, in particular. The current 
study results suggest that treatment expectancy may be especially important for 
adolescents prior to treatment initiation with mild to moderate depression, although it 
may become more important (in combination with acceptance of treatment rationale) for 
those with marked to severe depression after treatment has begun. In TADS, both 
treatment expectancy and treatment assignment predicted treatment response. Therefore, 
it is not the case that the former accounts for COMB’s superior performance in TADS. 
Rather than seeing treatment expectancy as a factor that must be controlled to isolate the 
effects of treatment (e.g. through blinded clinical research trials), it is perhaps more 
fruitful to view expectancy as an active ingredient in psychotherapy, and instead find 
ways to increase its potency.  
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APPENDIX A 
 
TEA 
 
How much do you expect your depression problems to improve with each of the 
following treatments? Circle your answers below. 
 
1=Very much improved 
2=Much improved 
3=Minimally improved 
4=Not changed 
5=Minimally worse 
6=Much worse 
7=Very much worse 
 
1. Cognitive Behavior Therapy 
1 2 3 4 5 6 7 
 
2. Medication only 
1 2 3 4 5 6 7 
 
3. Combined  Cognitive Behavior Therapy with medication 
1 2 3 4 5 6 7 
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APPENDIX B 
 
C-RAIE 
 
Please rate each of the following items on a scale of 1 (“strongly disagree”) to five 
(“strongly agree”) based on your agreement with the statement.  
 
1=Strongly disagree 
2=Somewhat disagree 
3=Neutral 
4=Somewhat agree 
5=Strongly agree 
 
 
1. What depression is made sense to me. 
 
1  2  3  4  5 
 
 
2. What CBT is made sense to me. 
 
1  2  3  4  5 
 
 
3.  How CBT will help made sense to me. 
 
1  2  3  4  5 
 
 
4. I expect I will have control over my depression through this treatment. 
 
 
1  2  3  4  5 
 
 
5. I expect to get better or less depressed through this treatment. 
 
 
1  2  3  4  5 
 
 
6. I expect life to get better through this treatment. 
 
 
1  2  3  4  5 
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